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Uterine leiomyosarcoma (LMS) is a rare malignant smooth muscle connective tumor, that 
represents the second most frequent uterine sarcoma after carcinosarcoma and it is associated 
with high rates of recurrence and a poor clinical outcome. Studies evidenced that sarcomas 
present a strong repression of MEF2 and the highest activation of class IIa HDACs: 
approximately 22% of leiomyosarcoma patients presents high levels of HDAC4, HDAC5 and 
HDAC9. SK-UT-1, a high grade uterine leiomyosarcoma cell line, reflects these features, as 
mirrored by the high protein levels of HDAC9 and HDAC4. We have recently demonstrated 
that high levels of HDAC9 arise from an increased transcriptional activity, in fact a chromatin 
immunoprecipitation on HDAC9 promoter of SK-UT-1 cells, revealed an impressive increase 
of most common modifications of histon 3, that positively support active gene transcription. 
The generation of SK-UT-1 cells knock-out for HDAC4 or HDAC9 lead to different 
outcomes: surprisingly, only the KO of HDAC9 increases the expression of some MEF2 
target genes, as indicated at mRNA level and by the detection of incresed H3K27 acetylation 
and H3K4me3. Ablation of HDAC9, obtained through the CRISPR/Cas9 technology, is able 
to significantly suppress the transformed phenotype of SK-UT-1 cells and our studies 
evidenced that the oncogenic activity of HDAC9 in high grade LMSs is mainly due to its 
capability to repress MEF2 transcription factors, consequently converting MEF2 proteins into 
transcriptional repressors. Further investigations highlighted that HDAC9 KO LMS cells are 
characterized by an increased expression of FAS receptor and a subsequent high susceptibility 
to cell death. Our purpose is to propose a new therapeutic approach consisting in targeting the 
tumor with a combination of drugs: class IIa HDACs inhibitors, to displace the repressive 
complex between HDAC9 and MEF2 on the promoter of some MEF2 target genes, in 
combination with other drugs actually used in clinical to treat LMSs, such as Doxorubicin. 
Overall, the strategy aims to reduce tumor aggressiveness and concurrently, to induce 
apoptosis of cancer cells. Preliminary data in vitro show strong synergistic effects of the novel 
compound NKL-54, suggesting its possible future translation into in vivo tumoral models.  
Overall, our study underlines how new epigenetic drugs can reprogram the tumor cells and 





AIM OF THE STUDY 
This PhD project starts from the observation that high grade uterine leiomyosarcomas are 
characterized by a frequent co-expression of MEF2 and the histone deacetylase 9. The aim of 
this work is to investigate the potential oncogenic role of HDAC9 in the tumorigenesis of 
LMSs and to clarify the transcriptional role of MEF2. To demonstrate the key role of HDAC9 
in the aggressivity of these tumors, we plan to knock-out HDAC9 using the CRISPR/Cas9 
technology in a high grade LMS cell line, SK-UT-1, and to describe the cell phenotype 
derived from gene ablation. Furthermore, we aim to selectively target the MEF2-HDAC9 
complex by using selective class IIa HDACs inhibitors. For this purpose, we selected a novel 
compound, NKL-54, which presents a backbone derived from BML-210. The high sensitivity 
to cell death of the SK-UT-1 cells HDAC9-/-, suggests to try a novel therapeutical approach 
consisting in the combination of the class IIa HDAC inhibitor NKL-54 with traditional 
mutagenic and cytotoxic agents, actually used in clinic. The potential enrichment of the 
apoptotic cell death derived from the combined strategy would be determined through the 
induction of caspases activity. In future, we hope that positive in vitro results would be 
















































1.1 Epigenetics: the meta-level of genetic regulation 
 
For a long time, it has been speculated that cancer is the result of genomic and genetic 
alterations, such as amplifications, deletions, translocations and point mutations. The dramatic 
consequence of these modifications is the activation of onco-genes and the inactivation of 
tumor-suppressor genes. However, cancer development is not only linked to genetic changes 
but may also involve epigenetic modifications (Weinhold B., 2006). The term “epigenetics” 
indicates the inheritance of informations based on gene-expression levels, as opposed to 
genetics, which consists in the transmission on the basis of gene sequence. The most 
significative epigenetic modifications in mammals, and particularly in humans, are the 
methylation of DNA and the modifications of the histones (phosphorylation, acetylation, 
methylation, ubiquitylation, sumoylation and others) that occur at post-translational level 
(Fig.1) (Ropero S. and Esteller M., 2007). These events are necessary for the regulation of 
various cellular functions, but if they occur improperly, there could be negative consequences 
on homeostasis. Until now, the best known epigenetic mechanism is the DNA methylation, 
that consists in the addition or removal of a methyl group (CH3) to the DNA, principally at 
cytosine rich motifs (Weinhold B., 2006). DNA methylation on the promoter of a gene is 
translated into transcriptional repression and this event may regulate several processes, 
including genomic imprinting, X-chromosome inactivation, aging and also carcinogenesis 
(Hackett JA. and Surani MA., 2013). The first evidences of methylated DNA in cancer cells 
have been detected in 1983 and further studies demonstrated its association also to various 
genetic disorders (Weinhold B., 2006).   
Chromatin is a tight complex of histone proteins and DNA localized inside the nucleus, 
(Annunziato A., 2008) and its modifications are also considered an epigenetic process. 
Several enzymes, RNAs and the addiction of acetyl groups (acetylation) can modify the 
histone-DNA complex, leading to chromatin structure and gene expression alterations. Amino 
groups of conserved lysine residues are often subjected to acetylation, which influences the 
activity of several proteins, such as transcription factors, histones and cytoskeletal proteins. 
Acetylation is a post-translational modification under the supervision of two antagonistic 
families of enzymes, the histone acetyl-transferases (HATs) and the histone deacetylases 
(HDACs), whose action should be strictly balanced (Ropero S. and Esteller M., 2007). The 
presence of acetylated lysines on histone tails is associated with a more relaxed chromatin 
state, favouring the recruitment of transcription factors on the promoter of specific genes, 
while the deacetylation of lysine residues is associated with a more condensed chromatin state 
and, consequently, to transcriptional gene silencing (Iizuka M. and Smith MM., 2003). 
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Moreover, a relaxed chromatin state is associated with other genome functions, such as 
chromatin assembly, DNA repair and recombination (Polo SE. and Almouzni G., 2015). The 
removal of acetyl groups from lysine residues by HDACs increases the ionic interactions 
between the positively charged histone proteins and the negatively charged DNA, promoting 
the compacting of the chromatin and the repression of gene transcription. The levels of 
histone acetylation play a crucial role in chromatin remodeling and in the control of gene 
transcription, in particular the acetylation of lysine residues of histone 3 (H3) and histone 4 
(H4). In addition, histone deacetylases are also involved in the deacetylation of non-histone 





Fig.1: Representation of the nucleosome and major histone modifications: acetylation, methylation, phosphorylation and ubiquitylation (Kim 
WY., 2014). 
 
1.2 General concepts on class IIa HDACs 
 
1.2.1 Histone deacetylases family (HDACs) 
 
In humans, eighteen histone deacetylases can be grouped into four different classes, according 
to their homology with gene orthologues in yeast (Rpd3, Hda1 and Sir2). Class I comprises 
HDAC1, -2, -3 and -8, that show homologies with Rpd3 gene, while class II includes 
HDAC4, -5, -6, -7, -9, -10 that present homologies with Hda1 gene. Class II HDACs are 
subdivided into classes IIa and IIb: histone deacetylase 4, -5, -7 and -9 belong to class IIa 
HDACs, whereas HDAC6 and 10 to class IIb. Class III includes Sirt1, 2, 3, 4, 5, 6 and 7 that 
are homologous to Sir2 in yeast and are also known as silent information regulators (SIR). 
HDAC11 represents the Class IV and its sequence shares similarities with both classes I and 
II (Fig.2) (Clocchiatti A. et al, 2013). Classes I, II and IV are characterized by a zinc-
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dependent catalytic mechanism, whereas the sirtuins present a NAD+-dependent catalytic 
mechanism (Clocchiatti A. et al, 2013).  
Classes I and II share homologies in the catalytic domain, but present some differencies in the 
N-terminal region, extended only in class II (Yang XJ. and Seto E., 2008). The peculiar N-
terminus domain of class IIa HDACs is involved in the interaction with relevant partners 
(Clocchiatti A. et al, 2013). Class I HDACs show preferentially a nuclear localization, 
whereas class II HDACs are present both in the nucleus and in the cytoplasm. Sirtuins are 
preferentially localized at subcellular level, such as in mitochondria (Clocchiatti A. et al, 
2011).  
The silencing of gene transcription exerted by class IIa HDACs occurs only in complex with 
different co-repressors; HDACs are involved also in non chromatin-related functions, for 
example in the deacetylation of non-histone proteins, including transcription factors involved 












1.2.2 Structure of class IIa HDACs and regulation of subcellular localization 
 
The class IIa includes HDAC4, HDAC5, HDAC7 and HDAC9. These proteins share similar 
features: an amino-terminal region, which binds to several transcription factors necessary for 
the targeting of DNA; a carboxy-terminal deacetylase domain that is enzymatically ‘inactive’ 
in vertebrates (or at least inactive for acetyl-lysines), but able to acquire a deacetylase activity 
through the assembly of multiprotein complexes; a nuclear localization sequence (NLS) and a 
nuclear export sequence (NES), which regulate the nuclear/cytoplasmic shuttling (Fig.3) (Di 




Fig.3: Schematic representation of class IIa HDACs structure (HDAC4) (Di Giorgio E. et al, 2015).  
 
Several post-translational modifications, such as sumoylation, phosphorylation and caspase 
cleavages can modify the amino-terminal domain (Martin M. et al, 2007). Regulation of class 
IIa HDACs subcellular localization occurs in response to specific extracellular signals that 
activate different serine/threonine kinases. CaMK I and CaMK IV, members of the 
calcium/calmodulin-dependent protein kinase family (CaMK) are the main proteins that 
perform this role (Martin M. et al, 2007). In muscle tissue, these kinases promote the export 
of class IIa HDACs from the nucleus, consequently promoting the activation of MEF2 target 
genes and the myogenic differentiation (Backs J. et al, 2008). To the CaMK superfamily also 
belong PKD, MARK1 and MARK2, which are involved in the regulation of class IIa HDACs 
shuttling (Hanks SK., 2003; McKinsey TA., 2007). PKD is a regulator of class IIa HDACs 
during angiogenesis, muscle remodelling and also in B and T cells and it is a downstream 
effector of the PKC pathway (Parra M. et al, 2005). MARK1 and MARK2 phosphorylate the 
first serine of the 14-3-3 binding site localized in the N-terminal region (Dequiedt F. et al, 
2006). Regulation of class IIa HDACs is obtained also by further kinases, such as the Salt 
inducible kinase 1 and Mirk/dyrk1B kinases (Berdeaux R. et al, 2007; Deng X. et al, 2005). 
PKA and GSK3-β are instead responsible of class IIa HDACs nuclear retention and protein 
degradation, respectively (Clocchiatti A. et al, 2011). HDACs localization is influenced also 
by phosphatases, which catalyze the removal of the phosphate groups. PP1 or PP2A stimulate 
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the nuclear accumulation of class IIa HDACs, in fact the treatment with some phosphatase 
inhibitors, such as the calyculin A and the okadaic acid, causes their cytoplasmic export 
(Paroni G. et al, 2008). The interaction with 14-3-3 proteins influences class IIa sub-cellular 
localization through different mechanisms: binding of 14-3-3 proteins can mask the NLS 
sequence, preventing the interaction with importin-alfa; alternatively, these interactions could 
promote a conformational change with the consequent exposition of the NES in the carboxy-
terminal region, favouring the nuclear export (Fig.4) (Grozinger CM. and Schreiber SL., 
2000). Thanks to the assembly of a multiprotein complex composed by HDAC3 and 
SMRT/N-CoR at the C-terminal domain, class IIa HDACs can exert their enzymatic activity, 




Fig.4: Shuttling of class IIa HDACs between the nucleus and cytoplasm. Phosphorylation of class IIa HDACs promotes their binding to 14-
3-3 proteins and their nuclear export. Dephosphorilation stimulates class IIa HDACs nuclear retention and the repression of MEF2 targets 
(Clocchiatti A. et al, 2011). 
 
1.2.3 Genomic organization of class IIa HDACs: an overview of HDAC9 
 
Class IIa HDACs subfamily is complexly regulated at gene transcription level and this is 
mainly due to the existence of several transcriptional variants. Up to now, only a single 
isoform of HDAC4 has been described and this is composed by 26 coding exons and 1 non-
coding exon (mRNA 8980 bp and ORF 3252 bp long) (Table 1) (Di Giorgio E. and 
Brancolini C., 2016). Two transcription variants are known for HDAC5: the longest RNA is 
5324 bp long and produces a 3369 bp ORF. The second transcription variant lacks the exons 
14 and 15 and encodes for a protein of 75 amino acids shorter, characterized by a deficient 
catalytic domain (Di Giorgio E. and Brancolini C., 2016). Two different splicing isoforms of 
HDAC7 have been characterized: the most common spliced isoform, which is composed by 
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25 exons, and the unspliced isoform with the first intron the follows the first ATG. The 
unspliced mRNA gives rise to two products: a small peptide of 7 amino acids and a protein of 
22 amino acids (Zhou B. et al, 2011). Zhou B. et al. (2011) describe how the splicing of 
histone deacetylase 7 modulates smooth muscle cell proliferation and how their generation is 




Table 1: Summary of the genomic localization of the different class IIa HDACs (Di Giorgio E. and Brancolini C., 2016). 
 
In this study we mainly focused on histone deacetylase 9. Multiple protein isoforms of 
HDAC9 derived from alternative splicing processes and all of them may have different 
biological functions. The full-length sequence of HDAC9 contains an open reading frame of 
3210 bp, which encodes for a protein of 1069 amino acids (exons 2–26, exon 1 is 
untranslated) (Petrie K. et al, 2003). MITR or HDAC9ΔCD (HDRP/MITR) is a truncated 
variant of HDAC9 (593 aa long), which lacks the deacetylase domain, therefore it is 
catalytically inactive  (Petrie K. et al, 2003) (Fig.5).  
 
 
Fig.5: Representation of the full length isoform of HDAC9 and MITR (Petrie K. et al, 2003). 
 
Evidences indicate that MITR accumulates in the nucleus and it is able to strongly repress the 
MEF2-dependent transcription, probably through the recruitment of co-repressors, such as 
CtBP (Zhang CL. et al, 2001) or the other class IIa HDACs (Zhang CL. et al, 2002). 
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1.2.4 Phylogenetic analysis of HDAC9 
 
By evaluating the similarities (in terms of amino acid sequences) of the deacetylase domain of 
HDAC9 with the ones of other class II histone deacetylases, it is emerged a high phylogenetic 
correspondence with HDAC5 (Petrie K. et al, 2003). Based on the analysis of the HDAC 
catalytic domain, it is possible to subdivide the class II histone deacetylase in a further group, 
consisting of HDACs -6, -10, and -11 (Fig.6). 
 
Fig.6: Phylogenetic analysis of HDAC9. In light gray are indicated the histone deacetylase domains and the percentage of amino acid 
identities (Petrie K. et al, 2003). 
 
1.2.5 Distribution of HDAC9 transcripts in normal and cancer cell lines 
 
Expression analysis of HDAC9 and its spliced isoforms, performed in various human tissues 
and cell lines, reveal that the full-lenght transcript and HDAC9ΔCD are more expressed in 
lung, skeletal muscle and in adult and fetal brain, although they are considerably more 
abundant in fetal tissue (Petrie K. et al, 2003). In normal hematopoietic tissues, the highest 
levels of the full-lenght HDAC9 were observed in cells expressing CD14 
(monocyte/macrophage) and, to a lesser extent, CD19 (B cell) surface markers. Low levels of 
HDAC9 isoforms presenting the catalytic domain are expressed in the bone marrow, thymus 
and spleen. Further inspections in hematopoietic cell lines show that HDAC9 isoforms 
present a differential expression in the B cells and cell lines derived from B cell tumors. 
HDAC9 is generally expressed in pre-B cell acute lymphoblastic leukemia cell lines, B cell 
lymphoma cell lines and also in the plasma cell line U-266. HDAC9 expression has been also 
detected in some T cells. In particular, the T cell leukemia cell line MOLT-3 preferentially 
expresses HDAC9ΔCD. HDAC9 is not expressed in any acute myeloid leukemia cell lines 
with the exception of KG1 (a multi-lineage lymphomyelocytic cell line), which highly 
expresses HDAC9ΔCD. Up to now, data suggest that within the hematopoietic system, 


















   
 
 
Fig.7: HDAC9 transcripts in different tissues. Upper panel shows the differential expression of HDAC4, HDAC9 and MITR in normal 
tissues and in leukemic cell lines.  Lower panel indicates the HDAC9 isoforms in the B cell lineage and cell lines derived from B cell tumors 
(Petrie K. et al, 2003). 
 
 
1.2.6 Class IIa HDACs binding partners 
 
To negatively influence the transcription, class IIa HDACs need to associate into 
macromolecular complexes inside the nucleus (Clocchiatti A. et al, 2011). To selectively bind 
the DNA, class IIa HDACs need to interact with specific transcription factors. Different 
interactors associate with the N-terminal domain of class IIa HDACs, such as MEF2 
(Myocyte Enhancer Factor-2), SRF (Serum Response Factor), RUNX2 (Runt Related 
Transcription Factor 2), CtBP (C-Terminal Binding Protein 1), or HP1 (Heterochromatin 
Protein 1). Actually, the MEF2 transcription factors family represents the most delineated 
class of HDAC binding partners (Arnold MA. et al, 2007; Li L. et al, 2018). Twelve amino 
acids localized in the N-terminal region of the deacetylase are involved in the binding to 
MEF2 (Di Giorgio E. et al, 2013). A mutant of HDAC4 deprived of these residues loses most 
of its functions (Di Giorgio E. et al, 2013). SRF is another member of the MADS box family 
of transcription factors and it is required for cell differentiation in diverse contexts (Owens 
GK. et al, 2004). RUNX2 belongs to the RUNX family of transcription factors and encodes a 
nuclear protein fundamental during the skeletal morphogenesis and the differentiation of 
osteoblasts (Vega RB. et al, 2004). Other transcriptional partners of class IIa HDACs are: 
GATA (Ozawa Y. et al, 2001), Forkhead (Liu R. et al, 2009), Ying and Yang 1 (Sucharov 
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CC. et al, 2008) and Hypoxia-inducible factors (HIFs) (Seo HW. et al, 2009). The recruitment 
of class IIa HDACs to DNA can be also driven by the association with hormone receptors 
inside the nucleus: estrogen receptor (ER) can interact with HDAC4, HDAC5 and HDAC9 
(Leong H. et al, 2005) and androgen receptor (AR) can be bound by HDAC4 and HDAC7 
(Karvonen U. et al, 2006). Several other potential partners of class IIa HDACs are still under 
investigation.   
 
1.3 The Myocyte Enhancer Factor 2 (MEF2) family of transcription factors 
 
1.3.1 The MEF2 family and gene mapping 
 
MEF2 proteins are members of the MADS-box (Minichromosome maintenance genes 
agamous deficiens and serum response factor) family of transcription factors (TFs). 
Drosophila, Caenorhabditis elegans and Saccharomyces cerevisiae present a unique MEF2 
gene, while vertebrates present four members: MEF2A (15q26), MEF2B (19q12), MEF2C 
(5q14) and MEF2D (1q12-q23) (Potthoff MJ. and Olson EN., 2007). MEF2 proteins of 
different species are composed by a similar N-terminal domain (composed by a MADS-box 
domain and an adjacent MEF2 domain), while the structure of the C-terminal transactivation 
domain is more heterogeneous (Potthoff MJ. and Olson EN., 2007). The sequences of 
MEF2A and MEF2C show high similarities, probably due to a duplication event, while 
MEF2B diverged from a single ancestral MEF2 gene (Potthoff MJ. and Olson EN., 2007). 
Differently from the transactivation domain, which presents a low amino acid identity (6%), 
the MADS and the MEF2 domains are well conserved among MEF2A and MEF2B, 
respectively for the 91% and 68% (Potthoff MJ. and Olson EN., 2007) (Fig.8).  
 
 
Fig.8: Conservation of the MADS-box, MEF2 and the transcriptional activation domains of MEF2 proteins between different organisms and 
human paralogues MEF2A, -B, -C, -D (Potthoff MJ. and Olson EN., 2007). 
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1.3.2 Structure of MEF2 proteins 
 
MEF2 proteins contain a N-terminal MADS-box domain, a central MEF2 domain and a C-
terminal transactivation domain. The MADS-box domain is a DNA-binding region (55 amino 
acids) essential for the recognition of the target sequences. MEF2 proteins also present an 
adjacent region of 29 amino acids, called central MEF2 domain, which, together with the 
MADS-box domain, allows the homo- and hetero-dimerization of MEF2 proteins, the binding 
to a conserved A-T rich DNA consensus sequence, YTA(A/T)4TAR (Anders V. et al, 1995) 
and the interactions with transcriptional co-activators and co-repressors (Chen X. et al, 2017).  
The carboxyl-terminal region of MEF2 proteins is a transcriptional activation domain (TAD). 
It is different across the family members and it is often subjected to alternative splicing 
(Potthoff MJ. and Olson EN., 2007). The C-terminal domain of MEF2 proteins also presents a 
nuclear localization signal (NLS) (Wang AH and Yang XJ., 2001). MEF2 TFs are weak 
transcription activators and for this reason they exert their functions by creating molecular 
complexes with other TFs or co-activators (Ma K. et al, 2005; Kong NR. et al, 2016). 
Moreover, MEF2 activities are usually regulated by transcriptional, translational and post-
translational modifications, such as phosphorylation, sumoylation, methylation, ubiquitylation 












1.3.3 MEF2 proteins regulate diverse developmental programs 
 
MEF2s are defined as pleiotropic transcription factors (TFs), which supervise genetic and 
epigenetic programs that control cell differentiation, proliferation, morphogenesis, survival 
and apoptosis (Potthoff MJ. and Olson EN., 2007). Their expression is higher in skeletal, 
cardiac and smooth muscle cells, but also in neurons, chondrocytes, lymphocytes and bones 
(Potthoff MJ. and Olson EN., 2007). MEF2A, MEF2B, and MEF2D proteins are ubiquitously 
expressed (Molkentin JD. et al, 1995), while MEF2C is more expressed in skeletal muscle, 
heart and brain (Edmondson DG. et al, 1994).  
Recent studies reveal the central role of MEF2 as regulator of several developmental 
programs, such as myogenesis, brain and lymphoid lineage development, endochondral bone 
ossification and vasculogenesis (Potthoff MJ. and Olson EN., 2007).  
In adult tissues, MEF2 proteins regulate remodeling programs, cell survival and proliferation 
(Potthoff MJ. and Olson EN., 2007). Activation of MEF2 proteins at the G0/G1 transition of 
the cell cycle is necessary to mediate the expression of the early genes in response to growth 
factor stimulation (Di Giorgio E. et al, 2015). MEF2 also triggers the CDK inhibitor 
p21/CDKN1A exerting and anti-proliferative effect (Di Giorgio E. et al, 2015). MEF2 exerts 
a crucial role in stress responses, such as cardiac hypertrophy (Zhang CL. et al, 2002) and it 
actively stimulates apoptosis of T-cells by inducing the expression of Nur77 (Youn HD. and 
Liu JO., 2000).  
Post-translational modifications and the interaction with transcriptional co-factors are 
mechanisms that drive MEF2 proteins towards opposing cellular decisions, such as 
differentiation, proliferation and apoptosis (Potthoff MJ. and Olson EN., 2007). 
 
1.3.4 Regulation of MEF2 activity by post-translational modifications 
 
MEF2 activity is under a complex regulation that occurs through different transcriptional, 
translational and post-translational mechanisms. Many post-translational modifications 
(PTMs), including phosphorylation, sumoylation, methylation and acetylation may enhance or 
suppress their activities during different cellular programs, such as cell differentiation and cell 
growth  (Pon JR. and Marra MA., 2015). Phosphorylation of MEF2 occurs at different sites: 
MEF2 proteins contain a single serine phosphorylation residue in the MEF2 domain and 
multiple phosphorylation sites in the transactivation domain. Studies demonstrate that the 
phosphorylation of Ser-59 in the MEF2 domain of MEF2C enhances the DNA binding and 
the transcriptional activity of MEF2C. This particular site is conserved in all members of the 
MEF2 family, highlighting its importance for the MEF2 functions (Molkentin JD. et al, 
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1996). Casein kinase II (CKII) is the enzyme involved in the phosphorylation of Ser-59 on 
MEF2. It is well known that the transactivation activity of many transcription factors is 
regulated by phosphorylation. The mitogen-activated protein (MAP) kinase family of 
serine/threonine kinases has been shown to play important roles in regulating MEF2 proteins: 
it has been previously described that the transactivation activity of MEF2A and MEF2C is 
stimulated by p38 mitogen-activated protein (MAP) kinase in response to growth or stress 
stimuli (Zhao M. et al, 1999). Kasler HG. et al. (2000) reported that also other MAPKs, such 
as JNK or ERK5, enhance the transcriptional activity of MEF2s, for example, in response to 
calcium flux in T cells. In contrast, by phosphorylating MEF2 in the transactivation domain, 
Cdk5 inhibits its activity and consequently, its protective effects in neurotoxicity-induced 
apoptosis (Gong X. et al, 2003). MEF2 proteins can also operate as transcriptional repressors, 
when they form complexes with co-repressors, through the binding with their N-terminal 
regulatory region. Phosphorylation of MEF2Dα1 by PKA provokes its association with class 
IIa HDACs during myogenesis (Sebastian S. et al, 2013). MEF2 activity can be also regulated 
by sumoylation: human MEF2D is sumoylated on Lys-439 and MEF2C Lys-391. 
Surprisingly, Cdk5 stimulates the sumoylation by phosphorylating Ser-444 that was also 
found to be essential for HDAC4 to stimulate the sumoylation (Grégoire S. et al, 2006). 
Studies evidence that also epigenetic modifiers regulate MEF2-dependent transcription via 
modifications of histones, in fact MEF2D can be methylated and demethylated at lysine 267 
by G9a and LSD1, respectively, regulating its target genes during skeletal muscle 
differentiation (Choi J. et al, 2014). The acetylation of MEF2 is also important for MEF2 to 
enhance its DNA binding and transcriptional activity: the histone acetyltransferases p300, 
PCAF and CBP acetylate MEF2 proteins on conserved lysine residues. The transactivation 
domain of MEF2C is, for example, a target of p300 in differentiating myocytes (Ma K. et al, 
2005). 
 
1.3.5 Roles of MEF2 in human diseases 
 
Many pathological conditions, including neurological disorders, cardiac dysfunctions and 
cancer are characterized by alterations of MEF2 activity (Pon JR. and Marra MA., 2015).  
Decreased levels of MEF2C produces the MEF2C haploinsufficiency syndrome 
(Paciorkowski AR. et al, 2013), while increased MEF2C expression has been associated with 
congenital heart defects (Friedrich FW. et al, 2013). Only recent studies demonstrated the 
involvement of MEF2 proteins in cancer development. Specifically, MEF2 proteins have pro-
oncogenic roles in hepatocarcinomas and in some hematological malignancies, which are 
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associated to increased expressions, mutations or genetic rearrangements of these 
transcription factors. By contrast, it has been described their actions as tumor suppressors in 
the case of soft-tissue sarcomas and in non-Hodgking lymphomas (Di Giorgio E. et al, 2017). 
 
1.3.6 Alterations of MEF2 in cancer 
 
1.3.6.1. Oncogenic activity of MEF2 family genes 
 
MEF2 proteins mainly act as oncogenes in hematological cancers. Increased MEF2C 
expression is characteristic of immature T-cell acute lymphoblastic leukemia (Homminga I. et 
al, 2011). In this kind of tumor, increased expression of MEF2C is frequently associated to 
rearrengements or alterations affecting interaction proteins and consequently, leading to the 
inhibition of cell differentiation. B-cell acute lymphoblastic leukemias also exhibit recurrent 
rearrangements producing oncogenic fusion proteins (Prima V. and Hunger SP., 2007). 
Studies demonstrate that MEF2C expression is increased in myeloid leukemia patients, 
promoting cell migration, invasion and high ability of colony formation. Its normal 
expression in myeloid progenitor cells suggests the possible involvement of MEF2C in 
conferring stem-cell like properties (Canté-Barrett K. et al, 2014). In contrast to MEF2C and 
MEF2D, up to now there are not implications of MEF2A and MEF2B in leukemia 
development (Pon JR. and Marra MA., 2015).  
MEF2 proteins are also involved in solid tumors: MEF2A, MEF2C and MEF2D mRNA and 
protein levels are increased in hepatocellular carcinoma cells and are associated to a poor 
prognosis (HCC) (Bai X. et al, 2008; Ma L. et al, 2014). It is reported that MEF2A, MEF2C 
and MEF2D promote epithelial-mesenchymal transition (EMT), favouring the acquisition of 
HCC cell invasiveness (Pon JR. and Marra MA., 2015). MEF2 proteins may have pro-
tumorigenic activities in other types of carcinoma, as in pancreatic ductal adenocarcinoma 
(Zhang JJ. et al, 2014). Reduced expression of YY1, a negative regulator of MEF2C 
expression, increases the invasiveness of pancreatic adenocarcinoma cells by the indirect 
activation of the MMP10 (Zhang JJ. et al, 2014). Although still not completely characterized, 
oncogenic roles of MEF2 proteins in other types of carcinoma may be predicted from the 
recurrence of MEF2 gene alterations. Data from the cBioPortal database report that 6-21% of 
ovarian serous cystadenocarcinomas, uterine endometriod carcinomas, lung squamous cell 
and adenocarcinomas, pancreatic adenocarcinomas, stomach adenocarcinomas, esophageal 
carcinomas, adrenocortical carcinomas and bladder urothelial carcinomas present an 
amplification of MEF2, whereas up to 2.6% of these cancers contain a deletion of MEF2 gene 




Fig.10: Carcinomas in which MEF2 proteins mainly act as oncogenes. Alterations affecting MEF2 genes are: gene amplifications (red), 
mutations (green), deletions (blue) and multiple alterations (grey) (Pon JR. and Marra MA., 2015). 
 
1.3.6.2 MEF2 family proteins as tumor suppressors 
 
Several studies highlight also tumor suppressor activities of MEF2 proteins. MEF2 target 
genes are repressed in lipo- and leiomyosarcomas (Di Giorgio E. et al, 2013; Di Giorgio E. et 
al, 2017) and this repression often correlates with decreased levels of MEF2C and MEF2D 
and increased expression of negative regulators of MEF2, such as HDAC4 and PI3K/AKT 
signaling (Di Giorgio E. et al, 2013). In rhabdomyosarcoma cells, MEF2D expression is 
usually lost (Zhang M. et al, 2013) and a less active isoform of MEF2C (α1) tends to be 
expressed compared to MEF2Cα2 (Zhang M. et al, 2015). These alterations are reflected into 
the inhibition of cell differentiation and the induction of cell proliferation, anchorage 
independent-growth and cell migration (Zhang M. et al, 2013; Zhang M. et al, 2015).  
Tremblay AM. et al. (2014) described a significant repression of MEF2C and MEF2D in a 
human embryonal rhabdomyosarcoma model, where YAP1 activity is elevated. The study 
reports how sustained YAP1 functions are responsible for the expression of two MEF2 
repressors, Twist1 and Cabin1, able to displace MEF2 proteins from the promoters of 
myogenic differentiation genes (Tremblay AM. et al, 2014). 
Muations of MEF2B have a crucial role in non-Hodgkin lymphomas: heterozygous somatic 
non-synonymous and indel mutations are reported in 8-18% of diffuse large B-cell lymphoma 
(DLBCL), 13% of follicular lymphoma (FL) and 3-7% of mantle cell lymphoma (MCL). 
MEF2B mutations at some residues (7% at K4, 8% at Y69, 33% at D83 in DLBCL and FL, 
and K23R mutations in MCL) give rise to nonsense, frameshift and stop codon read-through 
mutations in the transactivation domain (Morin RD. et al, 2011). Studies speculate that loss of 
 21 
MEF2B activity may repress DLBCL cell chemotaxis, favouring the cell migration outside of 
germinal centers and therefore contributing to DLBCL and FL development. In HEK-293 
cells, alterations of MEF2B are correlated to increased expression of the oncogene MYC and 
reduced levels of the tumor suppressor, TGFB1 (Pon JR. et al, 2015). Although the impact of 
the MEF2 on tumorigenesis is still undefined, tumor-associated alterations have been recently 
observed also in estrogen receptor-positive (ER) breast cancer (Clocchiatti A. et al, 2013). 
Studies evidenced a correlation between the down-regulation of some MEF2 target genes and 
the aggressiveness of ER+ breast tumors. Moreover, data revealed an association between 
increased class IIa HDACs expression and reduced patient’s survival (Clocchiatti A. et al, 
2013). In particular, class IIa HDACs display a pro-survival effect by repressing the pro-
apoptotic NR4A1/Nur77 (Clocchiatti A. et al, 2013).  
Breast cancers overexpressing the tyrosine kinase receptor HER2 (also known as ERBB2) 
present significant dysregulation of the MEF2–HDAC axis: HDAC7 is over-expressed, while 
some MEF2-target genes are strongly repressed (Clocchiatti A. et al, 2015).  
The investigation of the epigenetic status of the CDKN1A promoter leads to evaluate the 
involvement of HDAC7 in the regulation of CDKN1A transcription; the recruitment of 
HDAC7 on CDKN1A promoter occurs at a specific region (+1.5 kb), where HDAC7 highly 
influences epigenetic changes and consequently, the recruitment of MEF2 proteins 
(Clocchiatti A. et al, 2015). Overall, the study suggests that the MEF2–HDAC axis controls 
cell proliferation, principally by modulating the CDK inhibitor p21/ CDKN1A. 
 
1.3.7 Tumorigenic potential of the MEF2-HDACs axis  
 
Gene expression can be influenced by class IIa HDACs, exclusively through the co-operation 
with some DNA-binding factors (Di Giorgio E. et al, 2013). The transcription factors MEF2 
are actually known as the main partners of the class IIa HDACs. The role of the MEF2-class 
IIa HDACs axis in tumorigenesis has been extensively studied by Di Giorgio E. et al. (2013), 
which propose a model that highlights the oncogenic potential of axis alterations. To 
determine the contribution of HDAC4 in cell growth and proliferation, a nucleus-localized 
version (TM) of HDAC4, defective in the 14-3-3 binding site, was expressed into murine 
fibroblasts (NIH 3T3 cells). HDAC4 TM expressing cells exhibit some morphological 
changes, overcome the contact inhibition and increase the motility and proliferation, revealing 
a transformed phenotype similar to that of HRasV12 transformed cells. NIH 3T3 cells, 
expressing HDAC4 TM, reveal their transforming properties also in immunosuppressed nude 
mice. 
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1.3.8 Dysregulation of MEF2-HDAC9 axis in cancer 
 
Immunological studies report the involvement of MEF2D in the tumorigenesis of childhood 
pre-B acute lymphoblastic leukemia (ALL). Genomic analysis evidence that in these kind of 
tumors, the introns of MEF2D and DAZAP1 are often subjected to chromosomal 
translocations t(1;19)(q23;p1), that give rise to MEF2D-DAZAP1 and DAZAP1-MEF2D 
chimeric proteins. When ectopically expressed, they are able to promote cell proliferation. 
Interestingly, the fusion of DAZAP1 to the C-terminal domain of MEF2D increases the 
transcriptional capabilities of MEF2D, while DAZAP1/MEF2D is no more able to bind the 
genomic DNA (Prima V. et al, 2005; Prima V. et al, 2007).  
Next generation studies allow the identification of further fusion proteins of MEF2D affecting 
pediatric patients. HDAC9, as consequence, is up-regulated by the chimeric MEF2D-BCL9 
and MEF2D-HNRNPUL1, contributing to the repression of genes essential for B-lineage 
differentiation, such as RAG1 (Liu YF. et al, 2016).  
Alterations of MEF2D and HDAC9 are documented also in solid tumors, such as in lung 
cancer and in rhabdoid cancer cell lines. In these contexts, it is frequent the overexpression of 
HDAC9 in combination with high levels of MEF2D, which lead to BRM silencing (Liu G. et 
al, 2017). HDAC9 and MEF2D bind to the promoter of BRM, a member of the multiproteins 
complex SWI/SNF, close to two insertional polymorphisms, consequently creating two MEF2 
binding sites (BRM-741: TTAAA and BRM-1321: TATTTTT). BRM expression may be 
restored by the specific HDAC9 inhibition that permits to regulate MEF2D transcriptional 
activity. Thus, this suggests how the epigenetic mechanisms drive the alteration of important 
regulators of chromatin status and gene expression in several contexts (Suvà ML. et al, 2013).  
From genetic dysregulations observed in tumorigenic contexts, it may be possible to 
reconstruct the missing pieces of a highly functional framework existing between MEF2D and 
HDAC9; physiologically, HDAC9 is a MEF2-target gene and MEF2D, as a transcriptional 
activator, binds to HDAC9 promoter favouring its transcription. Moreover, this interaction is 
also governed by a strong negative feed-back: the HDAC9 repression leads to the down-
regulation of MEF2D activities, maintaining the physiological levels of both proteins. 
Therefore, high levels of HDAC9 and MEF2D in tumorigenical context may be explained by 




Fig.11: Schematic representation of the negative feedback mechanism between HDAC9 and MEF2D in normal and in tumorigenic contexts 
(Di Giorgio E. et al, 2018). 
1.3.9 Sarcomas as a model to study the MEF2-HDACs axis in cancer 
 
A deep investigation of several cancer types, done by scrutinizing the Oncomine database, 
revealed that soft-tissue sarcomas are characterized by the strongest alteration of the MEF2-
HDAC axis (Di Giorgio E. et al, 2013). 
In details, 25 genes containing a MEF2-binding site in the proximal promoters were found to 
be significantly repressed by HDAC4 in soft tissue sarcomas and in particular in 




Fig.12: Expression of the MEF2 target genes in human tumors. In light-blue are indicated tumors where the MEF2 signature is significantly 







1.4 Soft tissue sarcomas: uterine leiomyosarcoma (LMS) 
 
Sarcomas are a group of tumors of mesenchymal origin (Xiao W. et al, 2013). These tumors 
are most common in the bones, muscles, cartilages, tendons, nerves, fat and blood vessels or 
any tissue that protects or supports the organs of human body (Singh Z., 2017). The most 
recent epidemiological data report that sarcomas represent about 20% of all solid tumors that 
arise in pediatric age and less than 1% of all solid malignant tumors in adults. Soft tissue 
sarcomas are the most diagnosed tumors, while malignant bone cancers represent just over 
10% of sarcomas (Burningham Z. et al, 2012). Soft tissue sarcomas (STS) can originate from 
adipocytes (liposarcoma), vascular tissues (angiosarcoma), peripheral nerve tissues 
(malignant peripheral nerve sheath tumor), smooth muscle (leiomyosarcoma) or striated 
muscle (rhabdomyosarcoma) and from others (such as undifferentiated pleomorphic 
sarcoma). Among soft tissue sarcomas, leiomyosarcoma (LMS) represents an extremely rare 
form of malignant smooth muscle tumor, which represents the 5-10% of soft tissue sarcomas 
(Fig.13) (Singh Z. et al, 2018). This type of cancer can often remain dormant for long periods 
of time, as well as recur after years. It is not very responsive to chemotherapy or radiation, 
thus it is considered a resistant cancer type (Reed D. and Altiok S., 2011).  
Actually, the main available treatments are based on surgery and radiotherapy, but 
unfortunately, 40% of treated patients develop local recurrences or metastasis. Because of 
these high percentages, therapeutic strategies in use are mainly palliative (Ducie JA. and 
Leitao MM., 2016).  
Recently, genomic studies classified more than 70 heterogeneous types of adult soft tissue 
sarcomas in two broad classes: sarcomas with a simple karyotype and those with a complex 
karyotype (Cancer Genome Atlas Research Network, 2017). 
Adult soft tissue sarcomas develop frequent copy-number alterations that mainly affect 
MDM2, TP53, CDKN2A, RB1 and ATRX genes. MDM2 gene is often subjected to 
amplifications in dedifferentiated liposarcomas (DDLPS), while deletions of TP53 are 
frequently detected in 9% of LMSs, 16% of undifferentiated pleomorphic sarcomas (UPS) 
and 12% of myxofibrosarcomas (MFS). RB1 deletions are found in 14% of LMSs, 16% of 
UPS, and 24% of MFS and deletions of CDKN2A are mostly found in 8% of LMS, 20% of 
UPS, and 18% of MFS (Cancer Genome Atlas Research Network, 2017). 
Studies on leiomyosarcomas highlight the high recurrence of deletions and mutations of 
PTEN, that affect the PI3K-AKT-MTOR signaling pathway; also frequent amplifications and 
up-regulations of IGF1R, AKT, RICTOR and MTOR have been described (Cancer Genome 
Atlas Research Network, 2017). Thanks to the recent progress in clinical studies, more 
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effective drugs for LMS patients have been proposed, in particular TORC1/TORC2 inhibitors 
and dual PI3K/MTOR inhibitors, that may overcome traditional MTOR inhibitors (e.g. 
everolimus and temsirolimus), due to their indirect effect on AKT up-regulation (Cancer 





Fig.13: Representation of a benign tumor of the myometrium (leiomyoma) and a malignant tumor of the same origin (leiomyosarcoma) 
(http://aftercervicalcancer.blogspot.com/2012). 
 
1.5 Inhibition of histone deacetylases in cancer therapy: a hope for the treatment of 
sarcoma 
 
Given their involvement in approximately all cellular functions and their indispensable roles, 
HDACs may not be considered at a first sight as attractive targets for therapy, due to the 
possible interference of HDAC inhibitors with several physiological processes and therefore 
high risk of side effects (Ceccacci E. and Minucci S., 2016). Indeed, at the biginning, the first 
HDAC inhibitors were characterized for their antitumoral properties in vitro, before the 
discovery that they were able to inhibit histone deacetylase proteins: their use in preclinical 
models, showed a significant therapeutic window, with a selective cytotoxicity against 
tumoral cells and weak effects on normal ones (Ceccacci E. and Minucci S., 2016). Histone 
deacetylase inhibitors (HDIs) represent nowadays a considerable class of epigenetic drugs 
under study, which represent an opportunity for cancer therapy for several aspects: the most 
important might be the possibility to revert drug resistance and secondly, to prevent non-
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responsiveness to anti-neoplastic drugs (Helin K. and Dhanak D., 2013). The applicability of 
HDIs in oncology may be useful for two main reasons:  
a) Cancer cells are characterized by an enhanced degree of heterochromatinization compared 
to normal cells, making cancer genomes inaccessible to DNA-damage response enzymes 
(Carrier F., 2013). 
b) Several tumor suppressor genes, including some pro-apoptotic genes, are inactivated in 
cancer cells because of ipo-acetylated or hyper-acetylated promoters (Hatziapostolou M. and 
Iliopoulos D., 2011). 
These observations have incited the treatment of cancer cells with small molecules that target 
HDACs to relax the chromatin, consequently allowing the activation of DNA-damage 
responses, and to restore acetylation state at promoters of key genes. Histone deacetylase 
inhibitors represent a new class of anti-cancer agents. They display cytostatic effects, 
especially through the induction of p21 and the blockage of the cell cycle (Richon VM. et al, 
2000) and the activation of apoptosis (Henderson C. and Brancolini C., 2003). Some HDIs 
stimulate in vivo the clearance of tumoral cells from the immune system (Maeda T. et al, 
2000; Magner WJ. et al, 2000) or block angiogenesis (Rossig L. et al, 2002; Deroanne CF. et 
al, 2002). Despite these promising anti-neoplastic properties, the use of HDIs in clinic is 
slower than expected, because of efficacy (most are observed in selected cancer types, 
especially in haematological diseases) and safety (typical side effects are fatigue, diarrhoea, 
bone marrow toxicity, thrombocytopenia) issues. In fact, up to now the US FDA (the United 
States Food and Drug Administration) approved only few HDAC inhibitors for the treatment 
of T-cell lymphoma: Vorinostat (2006), Romidepsin (2009), Belinostat (2014) and 




Table 2: Classification of HDAC inhibitors: chemical class, targeted HDACs and status of phase trial (Ceccacci E. and Minucci S., 2016). 
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Considering the recent evidences about the pro-oncogenic properties of class IIa HDACs 
(Wilson AJ. et al, 2008; Clocchiatti A. et al, 2011) and their impact on epigenetics (Hohl M. 
et al, 2013), a way to bypass the side effects of current HDACs inhibitors might consist in 
targeting class IIa HDACs. 
 
1.5.1 Selective class IIa HDACs inhibitors  
 
Three different peculiarities of class IIa HDACs have been exploited to design specific 
inhibitors (Di Giorgio E. et al, 2015): 
 
a) Targeting the catalytic site (Zn2+ binding domain). 
b) Targeting the shuttling between nucleus and cytoplasm. 
c) Targeting the amino-terminal domain. 
 
a) Targeting the catalytic site (Zn2+ binding domain) 
 
The study and the careful characterization of the crystal structure of the class II deacetylase 
domain has encouraged the development and the synthesis of many inhibitors, able to 
selectively target class II histone deacetylases. Most of inhibitors are hydroxamates 
compounds, stemmed from SAHA (Vorinostat) structure, targeting the catalytic site of 
HDACs (Fig.14) (Henkes LM. et al, 2012). The realization of SAHA derivatives, with higher 
specificity against class II HDACs, required small modifications of the CAP, the hydrophobic 
domain that interacts with aminoacids delimiting the deacetylase catalytic site, and of the 
ZBG, the zinc binding group, capable of chelating the Zn2+ in the catalytic sites of HDACs 
(Marek L. et al, 2013). Selective targeting of class II HDACs also required some changes in 
the connecting unit (CU), generally a linker hydrophobic region that mymics the acetyl-lysin, 
to better fit to the peculiar hydrophobic catalytic site of class II deacetylases (Di Giorgio E. et 





Fig.14: Crystallographic structure of SAHA bound to the pocket of the catalytic site of HDAC4 (Richon VM., 2006). 
 
The most characterized hydroxamates-like drugs (SAHA derivatives) are: 
  
• MC1568 and MC1575 that are debated selective class IIa histone deacetylase inhibitors 
specific for HDAC4 (Fleming CL. et al, 2014; Mai A. et al, 2005; Duong V. et al, 2008) and 
HDAC6 (Saito S. et al, 2011; Lemon DD. et al, 2015). They derived from class I HDACs 
inhibitors aroyl-pyrrolyl-hydroxyamides (APHAs) modified in the linker hydrophobic region. 
These two synthetic compounds seem to be selective for class IIa HDACs and evidences 
indicate their anti-proliferative effects in vivo and in vitro. Suppression of IL-8 expression in 
human melanoma cells (Venza I. et al, 2013) and the strong induction in p21waf1 gene and 
protein expression in breast cancer cells, confirm their efficacy. However, the effective 
inhibition of class IIa HDACs has been claimed (Lemon DD. et al, 2015). 
• Recently was found that a series of diphenylmethylene hydroxamic acids can act as novel and 
selective class IIa HDACs inhibitors. The original compound, N-hydroxy-2,2-
diphenylacetamide (compound 6 in the original manuscript) has sub-micromolar class IIa 
HDAC inhibitory activity and the rigidified oxygen analogue N-hydroxy-9H-xanthene-9-
carboxamide (compound 13 in the original manuscript) presents a structure that makes it more 
selective for HDAC7 (Tessier P. et al, 2009). 
TMP-195 and TMP-269 are class IIa HDACs specific inhibitors in which the classical 
hydroxamic Zn2+ binding domain, typical of class I HDIs, is substituted by a 
trifluoromethyloxadiazolyl group (TFMO) (Lobera M. et al, 2013). The ring structure of 
TFMO group increases their stability and, differently from hydroxamate, it acts as a non-
chelating metal binding group, which interacts with the “catalytic” Zn2+ through weak 
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electrostatic interactions. As a consequence, the TFMO molecules have fewer off-targets 
compared to hydroxamates. Bonelli S. et al. (2018) proposes the novel inhibitor TMP-195 as 
a promising candidate for immunological diseases, given its ability to modify the tumor 
microenvironment by favouring the recruitment and differentiation of highly phagocytic and 
immunostimulatory macrophages within tumors (Bonelli S. et al, 2018). Evidences of anti-
neoplastic properties of TMP-195 are reported also by Guerriero JL. et al. (2017) with a 
transgenic mouse model of luminal B-type mammary carcinoma, in which this novel drug is 
able to promote tumor suppression by enhancing the antitumor activity of macrophages that 
boost activation of cytotoxic T lymphocytes (Guerriero JL. et al, 2017). In vivo treatment 
induces changes in monocyte gene expression without affecting lymphocyte gene expression 
and promotes a type 1 proinflammatory monocyte phenotype. 
• LMK235 ((N-((6-(hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide) (compound 19i 
in the original manuscript) represents an innovative evolution of hydroxamate-based HDAC 
inhibitors. The chemical modification that improved its selectivity toward human HDAC4 and 
HDAC5, is the novel alkoxyamide connecting unit linker region (Hansen FK. et al, 2014). 
When compared to Vorinostat, the compound LMK235 significantly enhances the cytotoxic 
effect on human ovarian carcinoma cells (A2780) and breast cancer cells (MDA-MB-231). 
The combination of LMK235 with cisplatin also contributes in enhancing the 
chemosensitivity of the sublines under investigation (Marek L. et al, 2013). 
Unconventional inhibitors (not SAHA derivatives) are: 
• Tasquinimod, that was not rationally designed or screened to target HDACs. Nevertheless, 
this carboxamide is able to enter the zinc-binding domain of HDAC4 keeping it in the 
inactive form and thus reorganizing the catalytic site of HDAC4 (Isaac JT. et al, 2013). The 
peculiarity of this drug is the selective targeting of the “structural” Zn2+ that represents the 
“core” of the Zinc Binding Domain, distinctive feature of class II HDAC catalytic site. Some 
authors proposed Tasquinimod as an anti-angiogenetic drug, since it suppresses the 
angiogenic switch induced by tumor hypoxia, resulting in an enhanced therapeutic feedback 
of prostate cancer cells to radiation (Dalrymple SL. et al, 2012). Anti-cancer efficacy is being 
evaluated in pre-clinical models and recently, Tasquinimod has entered registration Phase III 
evaluation for the treatment of castration resistant prostate cancer.  
• Ethyl 5-(trifluoroacetyl) thiophene-2-carboxylate is the founder of a class of compounds, the 
trifluoroacetylthiophenes, which targets with a discrete specificity class II HDACs. From a 
chemical point of view, this molecule is composed by a trifluoromethyl ketone group, which 
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chelates the active site zinc in a bidentate manner, the central thiophene ring, that fits 
perfectly to class IIa active site, and the amide group that interacts with the surrounding 
residues (Jones P. et al, 2008). 
 
b) Targeting the shuttling between nucleus and cytoplasm 
 
Since are demonstrated the oncogenic properties exerted by class II HDACs when localized 
into the nucleus (Di Giorgio E. et al, 2013), the strategy that it has been adopted is to interfere 
with class II HDACs nuclear accumulation. Some studies demonstrate the possibility to block 
class II HDACs in the cytoplasm by generating molecular compounds starting from the 
structure of SAHA, through the substitution of the amino-phenyl group with a fluorescent 
dansyl group (Kong Y. et al, 2011). This modification increases the specificity for class II 
HDACs, reducing the reactivity against class I HDACs. The consequence is that HDAC4 is 
bound to the inhibitor, thus impeding the interaction with importin-1a. Nevertheless, some 
drawbacks are still under investigation, in particular the fact that class IIa HDACs also 
possess cytoplasmic functions and, moreover, that the cytoplasmic accumulation could be an 
indirect effect of class I HDACs inhibition. Panobinostat (LBH589) is a representative drug 
belonging to this category and it derives from SAHA structure. It has been reported its ability 
to restrict HDAC4 localization in the cytoplasm in irradiated non-small cell lung cancer 
(Geng L. et al, 2006). 
 
c) Targeting the amino-terminal domain  
 
Class IIa HDACs are characterized by an exclusive N-terminal regulatory domain, which 
allows the homo and hetero-dimerization among the different class IIa members. This 
regulatory domain, which contains a glutamine-rich sequence (with the exception of 
HDAC7), is involved in the interaction with several partners, among which MEF2 proteins. In 
fact, several of the biological functions attributed to class IIa HDACs are due to the repression 
of MEF2 transcription. The design of an inhibitor that selectively displaces class IIa HDACs 
from binding MEF2 is extremely hard, since this aminoacid sequence is also involved in the 
interaction with other important proteins, one of which is p300. Starting from this issue, 
several groups decided to approach with an alternative strategy, which consists into targeting 
the region of MEF2 that interacts with class IIa HDACs. Crystallographic analyses and in 
vitro biochemical studies reveal that a short amphipathic helix conserved in the N-terminal 
regulatory domain of class IIa HDACs binds to a highly conserved hydrophobic groove on the 
MADS-box/MEF2 domain of MEF2. These studies suggest that the recruitment of class IIa 
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HDACs to DNA could be blocked by some small molecules binding to the hydrophobic 
pocket of MEF2, thereby inhibiting the sequence-specific genomic targeting (Lu J. et al, 
2000). Jayathilaka N. et al. (2012) used X-ray crystallography and NMR to identify and 
characterize a group of small molecules that target class IIa HDACs by blocking their binding 
with MEF2 (Fig.15). The result is an exclusive indirect strategy to prevent HDACs activity on 
gene transcription. The screening identified small molecules from the pimeloylanilide o-
aminoanilide (PAOA) class and further analyses focused on the most promising member of 
this family, N-(2-aminophenyl)-N0-phenyloctanediamide, which is commercially available as 
BML-210. This compound provides the first example of subtype-selective inhibition of 
HDACs by targeting the protein complex between class IIa HDACs and MEF2 and disrupting 
the co-localization of a class IIa HDACs and MEF2 in vivo (Jayathilaka N. et al, 2012). As 
BML-210 is a pan HDAC inhibitor (it inhibits also HDAC3 and Sirtuins in the micromolar 
range), its crystal structure has been used to guide the synthesis of more powerful BML-210 
analogs, highly specific for targeting the MEF2-class IIa HDACs interaction. Preliminary 
results obtained in sarcoma cell lines demonstrated that BML-210 and its analogues could be 
a promising treatment for this type of tumor (Di Giorgio E. et al, 2013). 
 

























































Cell cultures and reagents 
 
The human leio-myosarcoma cell lines SK-UT-1 and DMR were cultivated in Dulbecco 
modified Eagle medium (DMEM), supplemented with 10% fetal bovine serum (FBS) 
(Euroclone), L-glutamine (2mM) (Euroclone), penicillin (100U/ml) and streptomycin 
(100g/ml) (Euroclone). SK-UT-1 HDAC4 KO cells were previously generated (Di Giorgio E. 
et al, 2017). Primary antibodies used are: anti-GFP and anti-HDAC4 (Paroni G. et al, 2004), 
anti-HDAC5 (Clocchiatti A. et al, 2015); anti-MEF2A (C-21 sc-313 Santa Cruz 
Biotechnology), anti-MEF2D (BD Transduction Laboratories); anti-Actin (Sigma-Adrich), 
anti-H3K27ac (ab4729) and anti-H3K27me3 (ab6002) (Abcam); anti-H3K4me3 
(GTX128954, GeneTex), anti-Caspase 3 (Santa Cruz) and anti-Caspase 8 (Santa Cruz).  
 
Antibody production 
Anti-HDAC9 antibody was produced by rabbit immunization with a His-tagged peptide of 
HDAC9 (aa 275-600) expressed in E.coli and elettroeluted from the unsoluble fraction. The 
same procedure was used to produce a GST-tagged fragment of HDAC9 that was irreversible 
fused and crosslinked to Affygel in order to affinity purify the policlyonal antobody from 
rabbit serum.  
 
RNA extraction, reverse-transcription and quantitative qRT-PCR 
 
Cell were lysed and homogenized directly on the culture dish by using TRI-REAGENT 
(Sigma-Aldrich). 1.0μg of the total isolated RNA was retro-transcribed by using 100 units of 
M-MLV (Moloney Murine Leukemia Virus) Reverse transcriptase (Life Technologies). qRT-
PCRs were performed using the Bio-Rad CFX96 real-time PCR detection system and SYBR 
green (KAPA Biosystems) technology. Data were analysed by comparative threshold cycle 
using the expression levels of two housekeeping genes, HPRT (hypoxanthine 
phosphoribosyltransferase) and GAPDH as normalizer genes. All reactions were done in 
duplicate. 
 
Generation of HDAC9 knock-out SK-UT-1 cells and lentiviral CRISPR/Cas9 infection 
 
To obtain HDAC9 knock-out clones, the CRISPR/Cas9 technology was applied. In particular, 
to improve the specificity of Cas9-mediated genome editing, it was used the strategy that 
combines the D10A mutant nickase Cas9 (Cas9n) with a pair of offset sgRNAs 
complementary to opposite strands of the target site (Ran FA. et al, 2013). Firstly, it was 
 35 
necessary a step of mutagenesis of Cas9 enzyme at the catalytic residue in the RuvC domain 
(D10A). Two complementary oligonucleotides containing the desired mutation, flanked by 
unmodified nucleotide sequences, were synthesized. The mutant strand synthesis reaction 
required 100ng of dsDNA template and 125ng of oligonucleotide primers. DpnI restriction 
enzyme digested the non-mutated DNA. Secondly, two guides against HDAC9 (exon 1) were 
synthetized in order to produce two single strand breaks simultaneously, respectively at 
nucleotide 60 and 74 of the genomic sequence: 
 
GUIDE 1: GAA|GCAGCTTCTGATAGCA 
GUIDE 2: GAACTTGACACGGCAGC|ACC 
 
The distance beetween the two guides is 19nt. Each guide was cloned into a different plasmid: 
the GUIDE 1 associated to Cas9n (D10A) was cloned into a lentiCRISPRv2 vector, while the 
GUIDE 2 into a pLXSN vector. 
HEK-293 cells (Human Embrionic Kidney) packaging cells were transfected with the relative 
plasmids. In particular, the cells were seeded 2.7*105/ml and transfected at 50% of confluence 
using the Calcium Phosphate method. 8.0μg of each vector carring the guide were tranfected 
in combination with 5μg of Δ8.9 plasmid (the packaging plasmid that brings gag, pol, env 
genes) and 1.8μg of VSV-G (envelope protein with CMV promoter). After 36h of incubation 
at 37°C, virus supernatant was collected, filtered through a 0.45 μm syringe filter unit, diluted 
in fresh growth medium (1:1) and finally completed with polybrene (8μg/ul). The mixture 
was used to infect SK-UT-1 recipient cells (seeded 0.8*105/ml), at 60% of confluence. To 
produce SK-UT-1 cells stably expressing both GUIDE 1 and GUIDE 2 against HDAC9, the 
virus surnatant of HEK-293 cells expressing lentiCRISPRv2 carring Cas9n and the GUIDE 1 
was used to infect SK-UT-1 cells stably expressing pLXSN GUIDE 2. Cells infected were 
selected with puromycin antibiotic. To obtain HDAC9 knock-out clones, the infected SK-UT-
1 cells were seeded in 96 multiwells in order to grow clones from one cell per well. The 
putative KO clones were screened by PCR, immunoblot and validated by Sanger sequencing. 












Fig.16: Schematic representation of HDAC9 genomic sequence. Vertical lines represent the introns and horizontal lines indicate the exons. 
The wild-type sequence (black) is compared to the two HDAC9 knock-out clones generated by nCas9. KO1 (red) presents a deletion of 16nt 




The protein sample preparation required a first SDS denaturating cell lysis in presence 
of protease and phosphatase inhibitors and of β-mercaptoethanol to reduce the intra and inter-
molecular disulfide bonds. Protein samples were sonicated and heated in boiling water for 5 
min before the electrophoresis. Proteins were then transferred to a 0.2μm pore-sized 
nitrocellulose membrane (Protran, Amersham) by an electroblotting device. Blocking of non-
specific binding was achieved through incubation with non-fat dry milk in tris-buffered 
saline (TBS) with the 0.1% of Tween 20. Blots were incubated with primary antibodies (1h at 
RT or overnight at 4°C). After washes, blots were incubated with peroxidase-conjugated goat 
anti-rabbit or goat anti-mouse antibodies (Sigma-Aldrich) for 1h at RT. Secondary antibodies 
(Sigma-Aldrich) were developed with Super Signal West Dura (Pierce Waltham). For primary 
antibody stripping, blots were incubated for 30 min at 60°C in stripping solution (62.5mM 




SK-UT-1 cells, SK-UT-1 HDAC9-/- (clone 167) and HDAC4-/- (clone 26) were seeded at 
0.8*105/ml. Cells were fixed with 3% paraformaldehyde and permeabilized with 0.1% Triton 
X-100. Secondary antibodies used were Alexa Fluor conjugated (Molecular Probes). Actin 
was labeled with Phalloidin-AF546 (Molecular Probes). Nuclei were stained with Hoechst 
33258 (Sigma). Imaged were performed with a Leica confocal scanner SP equipped with a 
488 λ Ar laser and a 543 to 633 λ HeNe laser. 
 
Invasion assay, soft agar assay and random cell motility measurement 
 





KO1 (clone 167): AATCCAGAA|GCAGCTTCTGATAGCAGAGTTTCAGAAACAGCATGAGCTC-------------|ACCAGGCTCA 
 
KO2 (clone D43): AATCCAGAA|- AGCTTCTGATAGCAGAGTTTCAGAAACAGCATGAGAACTTGACACGGCAGCACCAGGCTCA 
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SK-UT-1 HDAC9-/- cells. For soft agar assay, equal volumes of 1.2% agar and DMEM were 
mixed to generate 0.6% base agar. A total of 0.5*105/ml sarcoma cells were seeded in 0.3% 
top agar and incubated at 37°C. The cells were grown for 15 days changing the culture 
medium twice per week. Foci were evidenced with MTT staining and counted by using 
ImageJ. For invasion assay, each well of the invasion chamber (CLS3428, Corning) was 
coated with 200μl of Matrigel matrix coating solution (Cultrex, Trevigen). Next, a cell 
suspension of 0.5*105/ml cells in 0.1% FBS-DMEM was added. As chemoattractant, 20% 
FBS-DMEM was added in each lower chamber. As a control 0.1% FBS-DMEM was used to 
evaluate random invasion. After 16h, cells were fixed and stained with Hoechst. 5 random 
fields were counted. 
Random motility was analysed by time-lapse video microscopy, as previously described 




For ChIP experiements, DNA-protein complexes were cross-linked with 1% fresh 
formaldehyde (Sigma-Aldrich) in DMEM for 15 min at RT. Cells were then collected directly 
from culture dishes with rubber scraper and lysed (5mM Pipes, 85 mM KCl, 0.5% NP40) in 
presence of protease inhibitors. The nuclear fraction was resuspended in RIPA-100 buffer and 
sonicated (Bioruptor UCD-200 (Diagenode) with pulses of 30 sec for 15 min to fragment 
DNA (average size of ~500bp). Samples were precleared and immunoprecipitated O/N at 4°C 
with: 1.5μg of anti-MEF2D and anti-MEF2A, 2μg of anti-HDAC4, 4μg of anti-HDAC9, 1μg 
of anti-H3K27ac, 2.5μg of anti-H3K4me3 and H3K27me3 antibodies or the same amount of 
control antibodies (FLAG M2 and USP33 serum). The IgG-DNA complexes were collected 
after incubation with protein A beads (GE Healthcare Bio-Sciences) blocked with BSA and 
salmon sperm DNA (1μg/μl) at 4°C for 90 min. Beads and inputs were treated with proteinase 
K at 56°C for 3h to degrade proteins and the cross-linking was reversed for 8-12h at 68°C. 
RNA was removed with RNAse A (10μg, Fisher Scientific). Genomic DNA was finally 
purified with Qiagen Qiaquick PCR purification kit and eluted in 100μl of water. 
 
BrdU (Bromodeoxyuridine) assay 
 
Cells were grown for 3h with 100μM BrdU and then fixed with 3% paraformaldehyde and 
permeabilized with 0.1% Triton X-100. Incubation with HCl (1N) for 10 min on ice permits 
to break open the DNA structure of the labelled cells. This is followed by HCl treatment (2N) 
for 10 min at RT and then the cells are incubated at 37°C for 20 min. After acid washes, 
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borate buffer (0.2M) is added to buffer the cells before the incubation of the mouse anti-BrdU 
antibody (Sigma-Aldrich). Secondary antibodies (AlexaFluor 488 or 533) were used for the 
detection. Nuclei were stained with Hoechst 33258 (Sigma-Aldrich). 
 
Proliferation assay  
 
SK-UT-1 Cas9, SK-UT-1 HDAC4-/- (clones 125 and 26) and HDAC9-/- (167 and D43) cells 
were seeded 0.3*105/ml in 12 multiwell plates. Cells were trypsinized and counted with a 
solution 0.1% Tripan blue. All experiments were done in triplicate. 
 
Resazurin reduction assay 
 
Cell proliferation/survival was measured for SK-UT-1 Cas9, SK-UT-1 HDAC4-/- (clones 125 
and 26) and HDAC9-/- (167 and D43) cells through the resazurin cell viability assay.  Cells 
were treated for 36h with several compunds at two increasing concentrations: Doxorubicin 
(50nM, 100nM), SAHA (2.5μM, 5μM), G5 (2.5μM, 5μM), Imatinib (10μM, 20μM), 
Lapatinib (10μM, 20μM), Metformin (10mM, 20mM) and MKK-2206 (10μM, 20μM). Initial 
cell seeding was at 0.8*105/ml. 
IC50 of BML-210, MKK-2206, SAHA, NKL-54 and TMP-195 was calculated in SK-UT-1 
and DMR seeded, respectively, at a confluence of 0.8*105/ml and DMR of 1.2*105/ml in 96-
well plate. Cells were treated for 36h with 4 increasing concentrations of drugs: BML-210 
(2.5μM, 5μM, 10μM, 20μM), MKK-2206 (5μM, 10μM, 20μM, 40μM), SAHA (0.5μM, 1μM, 
2μM, 4μM), NKL-54 (2.5μM, 5μM,10μM, 20μM), TMP-195 (5μM, 10μM, 20μM, 40μM). 
Each well contained a final volume of 100µl (medium and compound). Resazurin dissolved in 
PBS to 0.15 mg/ml was added 1:1 to each well and the plate incubated at 37°C for 2h. Viable 
cells with an active metabolism are able to reduce resazurin (violet) into resorufin (pink). 
Quantification was done using a microplate fluorometer (PerkinElmer EnSpire 2300 
Multilabel Reader) at 560 nm excitation/590 nm emission. 
 
Generation of SK-UT-1 and DMR cells over-expressing FLIPs (Neo) or FLIPs (Puro) 
 
To obtain SK-UT-1, SK-UT-1 HDAC9-/- and DMR cells with a stable expression of FLIPs, a 
protocol that provides a transfection followed by a retroviral infection was used. Ampho cells 
(cells of packaging) were transfected with calcium phosphate: a solution containing HBS2X 
(Hepes buffered saline solution) and a solution containing the plasmid DNA (12μg Pwzl 
Neo/pLPC Puro or 12μg Pwzl Neo FLIPs/pLPC puro FLIPs) and calcium chloride (CaCl2) 
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were prepared. The solution containing DNA was added to HBS2X and the creation of 
precipitates was encouraged by the formation of bubbles. The mix was incubated at RT for 20 
min, then added dropwise to Ampho cells layer and incubated at 30°C. Virus generated from 
packaging cells was used to stably infect recipient cells, SK-UT-1 (Pwzl Neo/pLPC Puro or 
Pwzl Neo FLIPs/pLPC puro FLIPs), DMR (Pwzl Neo/Pwzl Neo FLIPs) and SK-UT-1 




A drug treatment was done for SK-UT-1 Puro and SK-UT-1 Puro/FLIPs, SK-UT-1 Neo and 
SK-UT-1 Neo/FLIPs, DMR Neo and DMR Neo/FLIPs and finally, SK-UT-1 HDAC9-/- clone 
167 Neo and 167 Neo/FLIPs and SK-UT-1 HDAC9-/- clone D43 Neo and D43 Neo/FLIPs. 
SK-UT-1 cells were seeded at a confluence of 0.8*105/ml and DMR of 1.2*105/ml. Cells 
were treated for 48h with different concentrations of several compounds, in single or in 
combination. SK-UT-1 Puro and SK-UT-1 Puro/FLIPs, DMR Neo and DMR Neo/FLIPs were 
treated with increasing amount of NKL-54 (1.25μM, 2.5μM, 5μM, 10μM). SK-UT-1 Puro 
and SK-UT-1 Puro/FLIPs were tested also for Doxorubicin (50nM), ABT-263 (100nM) and 
MKK-2206 (10μM) and for a combined therapy of NKL-54 (5μM) and Doxorubicin (25nM), 
NKL-54 (5μM) and ABT-263 (100nM), NKL-54 (5μM) and MKK-2206 (10μM). DMR Neo 
and DMR Neo/FLIPs were treated with NKL-54 (5μM), Doxorubicin (50nM) and a 
combination of NKL-54 (5μM) and Doxorubicin (25nM). SK-UT-1 Neo, SK-UT-1 
Neo/FLIPs, SK-UT-1 HDAC9-/- clone 167 Neo and 167 Neo/FLIPs, clone D43 Neo and D43 
Neo/FLIPs were single treated with MKK-2206 (20μM), Doxorubicin (50nM) and G5 (5μM). 
All the treated cells were tested at flow cytofluorometry and for the caspases activity. 
 
Flow cytofluorometric analysis by propidium iodide staining 
 
SK-UT-1 and DMR cell lines were seeded in 35mm plates at a confluence of 0.8*105/ml and 
1.2*105/ml, respectively. After 48h of drug treatment, cells were collected and centrifuged at 
2000 rpm for 5 min. After one wash with PBS 1X, cells were centrifuged and the pellet 
resuspended in 100μl of PBS 1X together with 10μg/ml of propidium iodide (Sigma-Aldrich). 
After 10 min of incubation at RT, protected from the light, cells were collected, washed and 
resuspended in 800μl of PBS 1X containing 1% formaldehyde (Sigma-Aldrich). After a 
fixation of 10 min on ice, cells were treated with RNase A (50μg/ml) (Sigma-Aldrich) for 15 





The assay for the measurement of the activities of caspase-3 and -7 (Apo-ONE Homogeneous 
Caspase-3/7 Assay by Promega) was performed in SK-UT-1, in the two SK-UT-1 HDAC9-/- 
clones and in DMR cell line. Cells were seeded at a confluence of 0.8*105/ml for SK-UT-1 
and of 1.2*105/ml for DMR into a 96-well plate, in duplicate. The test required to mix a lysis 
buffer with a profluorescent substrate; upon sequential cleavage and removal of the DEVD 
peptides by caspase-3/7 and excitation at 499nm, the rhodamine 110 is released, emitting 
green fluorescence. For each well, the mixed solution was aliquoted (1:1 with the medium) 
and the multi-well was incubated at 37°C for 30 min. Fluorescence reading and quantification 
was performed using the PerkinElmer EnSpire 2300 Multilabel Reader. 
 
DNA Microarray  
 
Total RNA was extracted using RNeasy columns (Qiagen). Aliquots of RNAs were amplified 
according to the specifications of the Illumina TotalPrep RNA Amplification Kit (Ambion). 
Hybridization on Illumina whole-genome HumanHT-12 v 4.0 chip (Illumina), scanning and 
background subtraction were done according to the manufacturer’s specification. Fold-change 
and p-values for each probe set were calculated using a moderated t-statistic in the limma 
package, with the variance estimate being adjusted by incorporating global variation measures 
for the complete set of probes on the array. The p-value data were then corrected for multiple 




For experimental data Student t-test was employed. Mann-Whitney test was applied when 
normality could not be assumed. p<0.05 was chosen as statistical limit of significance. For 
comparisons between samples >2 Anova test was applied, coupled to Krustal-Wallis and 
Dunn's Multiple Comparison Test. We marked with * p<0.05, ** p<0.01, *** p<0.001. 
Unless otherwise indicated, all the data in the figures were represented as arithmetic means + 


























































3.1 Summary of the published works 
 
For many years, the role of class IIa HDACs in cancer has been intensely investigated. 
Nevertheless, these studies have not yet led to a conclusive and definitive role of these 
enzymes during the neoplastic progression. The oncogenic potential of class IIa HDACs has 
been firstly demonstrated in NIH-3T3 mouse immortalized fibroblasts (Di Giorgio E. et al, 
2013; Barneda-Zahonero B. et al, 2015; Witt AE. et al, 2017) and only recently, in primary 
human fibroblasts (Paluvai H. et al, 2018).  
Cancer-associated metabolic adaptations represent a new interestingly line of research and our 
aim was to better understand the impact of class IIa HDACs on the main metabolic pathways. 
In vitro transformation of NIH-3T3 cells with the nuclear version of HDAC4, failed to switch 
towards an anaerobic glycolytic phenotype, which mainly characterizes RAS-transformed 
fibroblasts. Instead, HDAC4 seems to be strongly involved in the regulation of the lipid 
metabolism and in the consumption of mitochondrial oxygen. In the oncogenic models under 
study, the acquisition of different metabolic phenotypes required the repression of a common 
group of MEF2 target genes (Peruzzo P. et al, 2016). 
Further investigations revealed that the repression of MEF2 transcription factors is higher in 
soft tissue sarcomas and in particular, in uterine leiomyosarcomas. In low grade LMSs (SKL-
LMS-1), the repression of a MEF2 signature is principally due to the higher degradation of 
MEF2 proteins, while in high grade tumors (SK-UT-1) this may be due to the envolvment of 
different MEF2 repressors. The silencing of MEF2D in the two cell lines triggers opposite 
responses, significantly reducing cell aggressiveness only in SK-UT-1 cells. This observation 
suggested a role for MEF2 also as transcriptional repressor, probably through the engagement 
of other co-factors, hence contributing to the cell malignancy (Di Giorgio E. et al, 2016). All 
these data have been published and included as additional material to this thesis. For this 















3.2 HDAC9, HDAC5 and MEF2 are increased in high grade leiomyosarcomas 
 
Leiomyosarcomas represent an excellent model to study the contribution of MEF2 to 
tumorigenesis, as their levels are high and frequently correlated with the overexpression of a 
class IIa HDACs member. By analyzing The Cancer Genome Atlas (TCGA) data of 
leiomyosarcomas we observed a frequent co-expression between HDAC4 and MEF2C, 
HDAC5 and MEF2A, and HDAC9 with MEF2D. In particular, it was evident the highest 
expression of MEF2D and HDAC9 in these aggressive types of tumors (Fig.17A). Based on 
these data, we hypothesized a key role of the MEF2D-HDAC9 axis in LMSs and the possible 
contribution to tumorigenesis derived from their inter-regulation.  
We further confirmed the up-regulation of HDAC9 in our cohort of 26 LMS patients by 
means of RNAseq analysis (Fig.17B). 
To study the molecular mechanisms behind the MEF2D-HDAC9 axis in LMSs, we validated 
the protein expression levels of MEF2 and class IIa HDACs in different uterine sarcoma cell 
lines: a grade II LMS cell line (SK-LMS-1), two grade III LMS cell lines (SK-UT-1 and 
DMR) and a carcinosarcoma cell line (MES-SA). SK-UT-1 cells are characterized by high 
levels of HDAC9, its splicing variant MITR, MEF2A and MEF2D; DMR have high 
expression levels of HDAC5, MITR and MEF2A. SK-LMS-1 cells are characterized by the 
lowest levels of the proteins under analysis (Fig.17C). Definitively, SK-UT-1 and DMR cell 
lines were selected for the further analysis, as their concurrent high levels of HDAC9, 






Fig.17: A) Oncoprint of TCGA leiomyosarcoma data for the z-scores of MEF2A, MEF2B, MEF2C, MEF2D and for class IIa HDACs in 100 
LMS samples. B) Scatter dot plot representing the coding mRNA TPM levels of the four class IIa HDACs in a cohort of 26 LMS samples. 
C) Immunoblot analysis of class IIa HDACs family members and MEF2 proteins in low grade (SK-LMS-1), high grade (SK-UT-1 and 
DMR) LMS cells and a poorly differentiated uterine sarcoma cell line MES-SA. Actin was used as loading control. 
 
3.3 The MEF2-HDAC9 axis  
 
MEF2 transcribes HDAC9 as part of a feed-back mechanism well known in literature 
(Haberland M. et al, 2007). Considering the frequent co-expression between MEF2D and 
HDAC9 in LMS, we wonder to know if a similar mechanism is operating in LMS cells.  
A luciferase assay revealed that HDAC9 expression could arise from the transcriptional 
regulation exerted by MEF2D, since its binding significantly increases the transcriptional 
activity of the HDAC9 promoter. The promoter activity was tested in HEK-293 cells 
transfected with the genomic region of HDAC9 promoter taken from primary fibroblasts 
IMR-90, a low grade LMS cell line, SK-LMS-1, and a high grade LMS cell line, SK-UT-1. In 
all the cases, MEF2 triggers HDAC9 promoter-driven luciferase activity at comparable levels, 
thus excluding any putative effect arising from the presence of any SNP in the proximal 
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promoter of HDAC9 (Fig.18B). Therefore, the high levels of HDAC9 observed in SK-UT-1 
cells could originate from an increased transcriptional activity exerted at its promoter. In fact, 
when SK-LMS-1 and SK-UT-1 were transfected with the promoter of HDAC9 isolated from 
SK-LMS-1 cells, the luciferase activity indicated an higher transcription of HDAC9 in SK-
UT-1 cells compared to SK-LMS-1 (Fig.18C). Next, it was investigated the consequences of 
MEF2D silencing on HDAC9 gene expression. The silencing of MEF2D in SK-UT-1 cells 
significantly reduces HDAC9 expression both at mRNA (Fig.18D) and protein levels 
(Fig.18E). ChIP analysis demonstrates the binding of MEF2 to the HDAC9 promoter region 
(Fig.18F) and that the binding event on this site dramatically enriches an epigenetic signature 
(an increase of H3K27ac and H3K4me3 and reduction of H3K27me3), typical of open 
chromatin/active transcription in SK-UT-1 cells (Fig.18G). 






Fig.18: A) Characterization of HDAC9 promoter. In blue are indicated the binding sites of MEF2A and in red the binding sites of MEF2C in 
the proximal promoter of HDAC9 (previously validated by ENCODE). B) Luciferase assay for HDAC9 promoter activity in HEK-293 cells 
transfected with MEF2D-GFP or GFP and the promoter region amplified from IMR-90, SK-LMS-1 and SK-UT-1 cells. 3xMEF construct, 
presenting three binding sites for MEF2, was used as positive control. Data are presented as mean and st.dev. n=3. C) SK-LMS-1 and SK-
UT-1 transfected with a pGL3 plasmid with the luciferase gene under the control of HDAC9 promoter isolated from SK-LMS-1 cells. 
Luciferase activity reveals a higher transcription of HDAC9 in SK-UT-1 cells compared to SK-LMS-1. Data are normalized by co-
transfecting pRenilla. D) HDAC9 and MEF2D mRNA levels after the silencing of MEF2D. Silencing of MEF2D was obtained with two 
distinct shRNAs in SK-UT-1 cells, as indicated. Data are presented as mean and st.dev. relative to control not silenced cells. n=3.  E) 
Immunoblot analysis indicates reduced protein levels of MEF2D induced by both shRNAs and reduced HDAC9 protein after MEF2D 
silencing. Actin was used as loading control. F) Chromatin was immunoprecipitated using the anti-MEF2D antibody (1.5μg) from SK-UT-1 
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cells WT or silenced for MEF2D by a shRNA. Mouse IgGs were used as control. Data are presented as mean and standard errors. n=4. G) 
ChIP analysis of the chromatin status in the MEF2D binding region. Chromatin was immunoprecipitated using the anti-H3K4me3, anti-
H3K27ac and anti-H3K27me3 antibodies (1μg) from SK-UT-1 cells and SK-UT-1 silenced for MEF2D. Data are presented as mean and 
standard error. n=3. 
 
3.4 The binding of HDAC9 to MEF2 gives rise to a repressive complex that contributes 
to tumor aggressiveness   
 
Principal features of high grade LMSs are the concomitant up-regulation of class IIa HDACs 
and the consequent switch of MEF2 into repressors, which direct the cells towards an 
aggressive tumorigenic phenotype. Previous experiments demonstrated that the knockdown of 
MEF2 in SK-UT-1 cells induced the up-regulation of a group of genes (Di Giorgio E. et al, 
2017). This peculiar gene response has been hypothesized to be due to a possible role of 
MEF2 as transcriptional repressors on these promoters. HDAC4 and HDAC9 were considered 
the most likely candidates for this role.  
The best way to test whether class IIa histone deacetylases were effectively the critical players 
to switch MEF2 into repressive transcriptional factors, was to generate SK-UT-1 cells knock-
out (KO) for HDAC4 or HDAC9. For this purpose, the CRISPR/Cas9 technology was 
applied. For each knock-out, two different clones were used for the further analysis 
(Fig.19A). Immunoblot assay shows the total ablation of HDAC9 protein and its splicing 
variant MITR in HDAC9 KO clones, in combination with increased levels of HDAC5 and 
MEF2D. Differently from HDAC9 KO clones, cells knocked-out for HDAC4 do not show a 
compensation for the reduced HDAC levels by increasing expression of HDAC9, while 
HDAC5 and MEF2D are slightly up-regulated.  
HDAC9 localizes mainly in the nucleus of SK-UT-1 cells (Fig.19B), while HDAC4 is 
pancellular and cytoplasmic, as a consequence of a strong nucleo/cytoplasmic shuttling 
(Fig.19C, compare HDAC4 distribution between untreated and leptomycin B treated cells).  
The immunofluorescence analysis of SK-UT-1 cells knocked-out for HDAC9 or HDAC4 
revealed that the morphology of the KO clones is different. In particular, HDAC9 KO cells 
exhibit a larger spread area in comparison to HDAC4 KO cells (Fig.19D-E). On this ground, 
we hypothesized that the KO of HDAC9 determines a re-differentiation of LMS cells and a 
lowering of their tumorigenic grade. As a matter of fact, the KO of both HDAC4 and HDAC9 
negatively impacts on the random motility of SK-UT-1 cells (Fig.19F), but only the KO of 




Fig.19: A) Immunoblot analysis of HDAC9, MITR, HDAC4, HDAC5, MEF2A and MEF2D in SK-UT-1 cells WT and in two KO clones for 
HDAC4 (125 and 26) and HDAC9 (167 and D43). Actin was used as loading control. B) Immunofluorescence analysis performed in SK-
UT-1 cells WT and HDAC9-/- stained for HDAC9 with an anti-HDAC9 antibody. Leptomycin B (50μg/ml), an inhibitor of nuclear export 
machinery, was used for 2 hours to confine the protein inside the nucleus. Anti-RAN antibody was used to stain nucleus. C) 
Immunofluorescence analysis performed in SK-UT-1 cells WT and HDAC4-/- stained for HDAC4 by using an anti-HDAC4 antibody. 
Leptomycin B was used to confine the protein inside the nucleus. Anti-RAN antibody was used to stain the nucleus. D) Immunofluorescence 
analysis performed in SK-UT-1 cells WT, HDAC4-/-, HDAC9 -/-stained for SMAC. Phalloidin AF546 was used to stain actin filaments. E) 
Dot plot representing the spread area of HDAC4-/- and HDAC9-/- cells quantified using Metamorph software. The median and the first and 
third quartiles are indicated. Dot plot representing the mean speed of HDAC4-/- and HDAC9-/- cells quantified using Metamorph software. 
The median and the first and third quartiles are indicated. F) Histogram representing the invasion rate of SK-UT-1 cells WT, HDAC4-/- and 
HDAC9-/-. Data are presented as relative to random migrating cells.  Mean and st.dev. are indicated n=3. G) Quantitative results of colony 
formation assay for SK-UT-1 cells WT, HDAC4-/- and HDAC9-/-. Data are presented as mean and st.dev. n=4. H) Representative images of 
the foci stained with MTT of SK-UT-1 cells WT and HDAC9-/-grown in soft agar for 18 days. 
 
3.5 A different gene expression profile characterizes SK-UT-1 cells HDAC4-/- or 
HDAC9-/-  
 
To understand the different roles played by HDAC4 or HDAC9 in SK-UT-1 cells, we 
compared the gene expression profiles of SK-UT-1 HDAC4-/- and HDAC9-/- cells.  
A DNA microarray analysis confirmed a different gene expression profile in SK-UT-1 cells 
knocked-out for HDAC4 or HDAC9. Genes up-regulated in SK-UT-1 cells HDAC4-/- were 
found to be poorly regulated in HDAC9-/- cells. Surprisingly, some of the genes induced in 
HDAC9-/- SK-UT-1 cells were even repressed in the HDAC4-/- cells (Fig.20A). This paradox 
could be explained as a consequence of the increased HDAC5 and MITR levels in HDAC4 
KO cells (Fig.19A).  
A Gene Onthology (GO) analysis indicated that the knock-out of HDAC4 in SK-UT-1 cells 
mainly induces the up-regulation of genes involved in the response to oxygen-containing 
compounds, in the programmed cell death and in the regulation of cell proliferation. The same 
analysis revealed a significant up-regulation of genes essential for the negative regulation of 
cell migration and locomotion and in the organization of actomyosin structures in SK-UT-1 
cell knocked-out for HDAC9. 
Reactome pathway analysis further highlighted the induction of genes involved in axon 
guidance, cellular response to external stimuli and in the signaling of Tyrosine Kinase 
receptor, when the expression of HDAC4 was abrogated. Wiki Pathways analysis identified in 
HDAC9-/- cells the up-regulation of genes related to lung fibrosis, TNF-alpha and FAS 
Ligand-induced apoptosis and stress induction of heat shock proteins. SK-UT-1 HDAC4-/- 






Fig.20: A) Heat map of the significant regulated genes in SK-UT-1 cells HDAC4-/- (clones 26 and 125) or HDAC9-/- (D43 and 167). The 
deepest blue indicates the up-regulated genes, repressed genes are indicated by intense green. B) Gene Onthology (GO), Reactome and Wiki 
Pathways analysis identified most common genes and related pathways up-regulated in SK-UT-1 HDAC4-/- or HDAC9-/-.  
 
3.6 The knock-out of HDAC4 and HDAC9 have a different impact on MEF2 proteins 
 
Genes found to be significantly up-regulated in SK-UT-1 cells HDAC4-/- and HDAC9-/- were 
further correlated to MEF2A and MEF2D activities by analyzing the gene expression profile 
of SK-UT-1 cells knocked-down for MEF2A or MEF2D (Di Giorgio E. et al, 2017). Results 
revealed that just a small group of genes repressed by HDAC4 were up-regulated by 
MEF2A/D KD (Fig.21A). When the same analysis was performed for the HDAC9-/- signature, 
a different result was obtained. Most of the genes repressed by HDAC9 were under the 
control of MEF2A and MEF2D (Fig.21A). Moreover, most of genes up-regulated in SK-UT-1 
cells HDAC9-/- correlate with a group of genes up-regulated in the same cells silenced for 
MEF2D/A (Fig.21B). We indicated as “atypical” this cluster of genes (Di Giorgio E. et al, 
2017), as on these loci MEF2 should normally act as a transcriptional repressor. 
 51 
A Gene Onthology (GO) analysis indicated that in SK-UT-1 cells KO for HDAC9, most of 
genes involved in the negative regulation of cell migration and locomotion and in the 
organization of actomyosin structures, depend on MEF2. Interestingly, it has emerged that the 
two main inductors of cell death, TNF and FAS Ligand were strongly dependent on MEF2 




Fig.21: A) Pie chart of most common up-regulated genes in HDAC4-/- and HDAC9-/- cells. Green and blue slices indicate, respectively, gene 
expression related to MEF2 repression and MEF2-independent repression. B) Gene set enrichment analysis (GSEA) obtained by overlapping 
the DNA microarray of shMEF2A/shMEF2D and shControl in SK-UT-1 cells with DNA microarrays relative to HDAC4-/- or HDAC9-/-. The 
NES and the significance of the enrichment are indicated. C) Table representing the Gene Onthology (GO) and WikiPathways analysis in 
SK-UT-1 HDAC4-/- or HDAC9-/-. The dependency from MEF2 was expressed as percentage. 
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3.7 HDAC9 KO cells are characterized by growth impairment and by a progressive 
reduction of survival 
 
The predicted activation of death pathways mediated by TNF and FAS-Ligand in SK-UT-1 
HDAC9-/- cells, led us to focus on the sensitivity of these cells to apoptosis. First of all, we 
tested the proliferative ability of SK-UT-1 HDAC9-/- cells in comparison to SK-UT-1 
HDAC4-/- and SK-UT-1 WT cells. BrdU assay indicated that HDAC9 KO cells are 
characterized by a significative proliferative deficit compared to SK-UT-1 HDAC4 KO cells 
(Fig.22A). Cell growth was instead measured by counting both living cells (Fig.22B) and the 
fraction of death cells (Fig.22C), after 5 days in culture. Cell growth was impaired both in 
HDAC4 KO and HDAC9 KO cells in comparison to SK-UT-1 WT cells, even if HDAC9-/- 
cells showed an impressive accumulation of cell death at day 5. Sensitivity of HDAC9-/- cells 
to apoptosis was also demonstrated by immunoblot analysis, which evidenced the higher 
expression of FAS receptor on the surface of the cells (Fig.22D). Moreover, cleavages of 
proCaspase-3 and proCaspase-9 indicated the activation of apoptosis in cells KO for HDAC9 
(Fig.22E).  
To further prove the increased sensitivity of HDAC9 KO cells to cell death, we challenged 
these LMS cells with different drugs that can have a therapeutic relevance such as: SAHA, 
G5, MKK-2206, Metformin, Lapatinib and Imatinib. Two increasing concentrations in control 
cells (SK-UT-1 Cas9), SK-UT-1 HDAC4-/- (clones 125 and 26) and HDAC9-/- (167 and D43) 
cells were tested. HDAC9 KO clones showed a reduced survival at highest concentrations of 
SAHA, G5, MKK-2206, Metformin and Lapatinib. Instead, the proliferation and survival of 





Fig.22: A) Histogram representing BrdU-positivity in SK-UT-1 Cas9 (control), SK-UT-1 HDAC4-/- (clones 125 and 26) and HDAC9-/- (167 
and D43) cells. Data are presented as mean and st.dev. n=4. B) Counting of living SK-UT-1 Cas9 (control), SK-UT-1 HDAC4-/- and 
HDAC9-/- clones, at day 1, day 2, day 3 and day 5 from seeding. Data are presented as mean and st.dev. n=3. C) Trypan blue staining of SK-
UT-1 Cas9 (control), SK-UT-1 HDAC4-/- (clones 125 and 26) and HDAC9-/- (167 and D43) cells at day 1, day 2, day 3 and day 5 from 
seeding. Data are presented as mean and st.dev. n=4. D) Immunoblotting analysis in SK-UT-1 Cas9 (control), SK-UT-1 HDAC4-/- (clones 
125 and 26) and HDAC9-/- (167 and D43) cells of the protein levels of FAS-R. Actin was used as loading control. E) Immunoblotting 
analysis in SK-UT-1 Cas9 (control), SK-UT-1 HDAC4-/- (clones 125 and 26) and HDAC9-/- (167 and D43) cells of the protein levels of 
Caspase 9 and Caspase 3. Cleavages of pro-Caspase-9 and -3 are indicated. Actin was used as loading control. F) Heat map indicating cell 
proliferation/survival of SK-UT-1 HDAC4-/- (clones 125 and 26) and HDAC9-/- (167 and D43) cells relative to untreated SK-UT-1 Cas9 cells 
after drug treatment at two increasing concentrations of each drug. 
 
3.8 The KO of HDAC9 induces activation of apoptotic cell death through the 
engagement of Fas receptor 
 
Experimental data indicated two main features of SK-UT-1 HDAC9-/- cells: the reduced 
proliferative ability and their high sensitivity to cell death. This increased susceptibility to cell 
death could be due to the increased expression of FAS receptor. To prove this we treated the 
cells with Fas Ligand (FasL). As expected, HDAC9 KO cells were more sensitive to FasL 
treatment in respect to WT cells (Fig.23A). To further confirm this point, we expressed FLIPs 
in both HDAC9+/+ and HDAC9-/- cells (Fig.23B). The generated SK-UT-1 Neo (as control) 
and Neo/FLIPs, SK-UT-1 HDAC9-/- D43 Neo and D43 Neo/FLIPs, and SK-UT-1 HDAC9-/- 
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167 Neo and 167 Neo/FLIPs cells were firstly treated with 25ng/ml of FasL (Fig.23C-D). 
HDAC9 KO cells appeared more sensitive to FasL treatment, while FLIPs over-expression 
induced only a partial reduction of cell death (Fig.23C-D). It is possible that the limited 
impact of FLIPs depends on the low levels of transgene expression. However, FLIPs over-




Fig.23: A) Cytofluorimetric analysis indicating the percentage of positive PI SK-UT-1 Cas9, HDAC9-/- 167 and HDAC9-/- D43 treated with 
increasing amount of FasL (25ng/ml and 50ng/ml). B) Immunoblot analysis of the protein levels of FLIPs in SK-UT-1 Cas9 Neo and Neo/ 
FLIPs, HDAC9-/- 167 Neo and 167 Neo/FLIPs and HDAC9-/- D43 Neo and D43 Neo/FLIPs. Actin was used as loading control. C) 
Cytofluorimetric analysis indicating the percentage of positive PI SK-UT-1 Neo and Neo/FLIPs, HDAC9-/- 167 Neo and 167 Neo/FLIPs and 
HDAC9-/- D43 Neo and D43 Neo/FLIPs treated with 25ng/ml of FasL. Data are presented as mean and st. dev. n=3. D) Caspase assay of SK-
UT-1 Neo and Neo/FLIPs, HDAC9-/- 167 Neo and 167 Neo/FLIPs and HDAC9-/- D43 Neo and D43 Neo/FLIPs treated with 25ng/ml of 
FasL. Data are presented as mean and st. dev. n=3. E) Cytofluorimetric analysis indicating the percentage of positive PI SK-UT-1 Neo and 
Neo/FLIPs, HDAC9-/- 167 Neo and 167 Neo/FLIPs and HDAC9-/- D43 Neo and D43 Neo/FLIPs. 
 
3.9 The KO of HDAC9 increases the sensitivity to conventional chemotherapeutic drugs 
 
The physiological activation of apoptosis observed in HDAC9-/- cells opened a window on the 
possibility to exploit this feature in a clinic perspective. In fact, the ablation of HDAC9 could 
be combined to conventional chemotherapeutic drugs, currently used in the treatment of 
leiomyosarcomas, potentially enhancing their therapeutic effects. To test this hypothesis, we 
treated the SK-UT-1 cells HDAC9-/- and HDAC9+/+, expressing or not FLIPs, with standard 
concentrations of the genotoxic Doxorubicin (50nM), the AKT inhibitor MKK-2206 (20μM) 
and G5 (5μM). Cell death was quantified by means of incorporation of propidium iodide (PI) 
and scored in flow cytofluorimetry. In comparison to the untreated cells, it was appreciable 
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the increased cell death fraction after the treatment with the anti-neoplastic molecules 
(Fig.24A) Furthermore, the percentage of cell death was significantly enriched in SK-UT-1 
HDAC9-/- cells in comparison to the SK-UT-1 control, demonstrating the additive effects of 
HDAC9 KO and Doxorubicin or MKK-2206 treatments (Fig.24A). Curiously, the anti-
apoptotic protein FLIPs significantly attenuated cell death in the cells treated with 
Doxorubicin, while it was much less effective with MKK-2206 compound. The same cells 
treated with Doxorubicin were screened for caspases activation, thus confirming the PI 
analysis and the activation of an apoptotic response (Fig.24B). 
 
 
Fig.24: A) Cytofluorimetric analysis indicating the percentage of positive PI SK-UT-1, HDAC9-/- 167 and HDAC9-/- D43 Neo and FLIPs 
cells, treated with Doxorubicin (50nM), MKK-2206 (20μM) and G5 (5μM). Data are reported as mean and st. dev. in the histogram. n=3. B) 
Caspase assay of SK-UT-1, HDAC9-/- 167 and HDAC9-/- D43 Neo and FLIPs cells treated with Doxorubicin (50nM). Data are presented as 
mean and st. dev. n=3. 
 
3.10 Class IIa HDACs inhibitors sensitize SK-UT-1 cells to cell death and differentiation 
 
Considered the increased activation of apoptosis and the sensitivity of SK-UT-1 HDAC9-/- 
cells to some conventional chemotherapeutic drugs, our aim was to mimic the effect of the 
knock-out of HDAC9 in the neoplastic cells under study. The approach that we propose is to 
treat SK-UT-1 cells with some HDACs inhibitors: for the analysis, we selected new potential 
class IIa HDACs specific compounds: NKL-54, a BML-210 derivative (Jayathilaka N. et al, 
2012) and TMP-195 (Guerriero JL. et al, 2017). Experiments compared the effectiveness of 
NKL-54 and TMP-195 with pan deacetylase inhibitors, such as SAHA (Richon VM., 2006) 
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and BML-210 (Jayathilaka N. et al, 2012). MKK-2206 was used as reference of cell death. 
IC50 of the selected drugs was calculated both in SK-UT-1 and DMR cell. SAHA showed the 
strongest effect on cell viability, but its low specificity for class IIa HDACs leads it to be the 
less beneficial therapeutic drug in a context of class IIa HDACs dysfunctions. BML-210 and 
NKL-54 showed a significant negative effect on cell growth. Less impact was obtained with 
TMP-195 (Fig.25A-B).  
A group of genes, all up-regulated by HDAC9 KO (Fig.25C), were selected to determine the 
transcription effects and specificity of the tested compounds. IL-8, a marker of inflammation 
and cell stress, ACTA2, a marker of cell differentiation and FAS receptor, a marker of cell 
death. Transcriptional analysis were performed by using the IC25 of each molecule and their 
effects were evaluated at 24 and 30 hours of treatment. The results indicated that both in SK-
UT-1 and DMR cells, NKL-54 and BML-210 induce IL8, FAS and ACTA2 at levels 
comparable to HDAC9 KO (compare Fig.25C with Fig.25D). SAHA regulates significantly 





Fig.25: A) Resazurin assay was applied to calculate the IC50 of BML-210, MKK-2206, SAHA, NKL-54 and TMP-195 in SK-UT-1 and 
DMR. Cells were treated for 40h with serial dilutions of the compounds: BML-210 (2.5μM, 5μM, 10μM, 20μM), MKK-2206 (5μM, 10μM, 
20μM, 40μM), and TMP-195 (5μM, 10μM, 20μM, 40μM), SAHA (0.5μM, 1μM, 2μM, 4μM) and NKL-54 (2.5μM, 5μM, 10μM, 20μM). B) 
Table indicating the IC50 and st.dev. of each drug in SK-UT-1 and DMR cells. C) mRNA expression levels of IL8, ACTA2, FAS were 
measured by qRT-PCR in HDAC9 KO clones 167 and D43. D) mRNA expression levels of IL8, ACTA2, FAS were measured by qRT-PCR 









3.11 NKL-54 sensitizes SK-UT-1 cells to apoptosis and synergizes with other drugs to 
trigger cell death  
 
NKL-54 was selected for further studies because of its capability to recapitulate the 
phenotype of the knock-out of HDAC9, in terms of genes activated and for its increased 
activity in comparison to BML-210, its derivative. SK-UT-1/Puro and SK-UT-1 Puro/FLIPs 
cells were generated and treated with increased concentrations of NKL-54 (1.25μM, 2.5μM, 
5μM and 10μM). Cell death was tested by propidium iodide (PI) assay. As reported in figure 
26A, the percentage of PI positive SK-UT-1/Puro cells increased by increasing the 
concentrations of NKL-54 and the results indicated that FLIPs expressing cells were less 
affected by NKL-54 treatment (Fig.26A).  
To demonstrate that the increased cell death after the treatment with NKL-54 was related to 
the activation of the apoptotic process, caspase-3 and -7 activities were measured. As shown 
in figure 26B, in SK-UT-1/Puro cells, the levels of caspases activation is proportional to the 
concentrations of NKL-54. The same trend was visible for SK-UT-1 Puro/FLIPs cells, despite 
at lower levels in comparison to control cells (Fig.26B). The experiment confirmed that the 
NKL-54 was toxic for the cells and the toxicity was attenuated by the inhibition of the 
extrinsic apoptotic pathway. This could be basically due to the expression of the anti-
apoptotic protein FLIPs, which significantly protected the cells from Caspase-8-dependent 
apoptosis (Kataoka T., 2005; Hughes MA. et al, 2016). Overall, this experiment demonstrated 
that cell death occurred principally as a result of caspases activation. 
Similar results were obtained in DMR/Neo cells and Neo/FLIPs (Fig.26C-D). Interestingly, 
the over-expression of FLIPs strongly decreased the pro-apoptotic activity of NKL-54 in 
DMR cells (Fig.26D). 
Cytofluorimetric analysis and caspase activation assay suggested that NKL-54 could be a 
promising drug to sensitize cancer cells to apoptosis, recapitulating the effect of the knock-out 
of HDAC9. Therefore, we evaluated whether NKL-54 could increase the cytotoxic effect of 
other compounds, such as Doxorubicin, MKK-2206 and ABT-263. For this purpose, SK-UT-
1/Puro and SK-UT-1 Puro/FLIPs cells were treated with NKL-54, ABT-263, a Bcl-2/xL 
inhibitor (Wang B. et al, 2014), Doxorubicin and MKK-2206, individually and in 
combination with NKL-54. As reported in Figure 26E, the single treatment of NKL-54 in SK-
UT-1/Puro cells triggers 20% of cell death, while Doxorubicin induces approximately 30% of 
cell death, as indicated by the percentage of PI positive cells. MKK-2206 and ABT-263 alone 
show a weaker impact on cell death. The co-treatment of the cells with NKL-54 and 
Doxorubicin displayed an additive effect that is partially blunted in FLIPs over-expressing 
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cells. A weak synergistic effect of NKL-54 can be appreciated when associated to MKK-2206 
and to ABT-263. Moreover, the experiment showed how, in the case of NKL-54 associated to 
MKK-2206, the effect is only partially recovered by FLIPs (Fig.26E). 
To confirm that the observed cell death phenotype was the consequence of the apoptotic 
process, the activation of caspases-3 and -7 was tested. The analysis was done for SK-UT-
1/Puro and SK-UT-1 Puro/FLIPs cells treated with MKK-2206, Doxorubicin, ABT-263 and 
NKL-54 individually and with a combination of NKL-54 and MKK-2206, NKL-54 and ABT-
263 and NKL-54 and Doxorubicin. The histogram (Fig.26F) shows that cell death was 
marked by caspase activation and the highest levels of activation occurred when cells were 
co-treated with Doxorubicin and NKL-54. This test also evidenced that cells treated with 
MKK-2206 and NKL-54 present a limited caspase activation, suggesting the co-occurence of 
caspase-independent cell death. The additive effects between Doxorubicin and NKL-54 was 









Fig.26: A) Cytofluorimetric analysis indicating the percentage of positive PI SK-UT-1/Puro and SK-UT-1 Puro/FLIPs cells treated with 
NKL-54 (1.25μM, 2.5μM, 5μM, 10μM). Data are presented as mean and st. dev. n=4. B) Caspase assay of SK-UT-1/Puro and SK-UT-1 
Puro/FLIPs cells treated with NKL-54 (1.25μM, 2.5μM, 5μM, 10μM). Data are presented as mean and st. dev. n=3. C) Cytofluorimetric 
analysis indicating the percentage of positive PI DMR/Neo and DMR Neo/FLIPs cells treated with NKL-54 (1.25μM, 2.5μM, 5μM, 10μM). 
Data are presented as mean and st. dev. n=4. D) Caspase assay of DMR/Neo and DMR Neo/FLIPs cells treated with NKL-54 (1.25μM, 
2.5μM, 5μM, 10μM). Data are presented as mean and st. dev. n=3. E) Cytofluorimetric analysis showing the percentage values of positive PI 
SK-UT-1/Puro and Puro/FLIPs cells, following individual treatment with NKL-54 (5μM), Doxorubicin (50nM), ABT-263 (100nM) and 
MKK-2206 (10μM) and after treatment with NKL-54 (5μM) in association with Doxorubicin (25nM), ABT-263 (100nM) and MKK-2206 
(10μM). Data are presented as mean and standard deviation. n=3. F) Caspase assay of SK-UT-1/Puro and SK-UT-1 Puro/FLIPs cells treated 
with NKL-54 (5μM), Doxorubicin (50nM), ABT-263 (100nM) and after treatment with NKL-54 (5μM) in association with Doxorubicin 
(25nM), ABT-263 (100nM) and MKK-2206 (10μM). Data are presented as mean and st. dev. n=3. G) Cytofluorimetric analysis indicating 
the percentage of positive PI DMR/Neo and DMR Neo/FLIPs cells after treatment with NKL-54 (5μM), Doxorubicin (50nM) and with 
NKL-54 (5μM) in association with Doxorubicin (25nM). Data are presented as mean and st. dev. n=3. H) Caspase assay of DMR/Neo and 
DMR Neo/FLIPs treated with NKL-54 (5μM), Doxorubicin (50nM) and with NKL-54 (5μM) plus Doxorubicin (25nM). Data are presented 


























Transcriptional dysregulation could be considered an emerging hallmark of cancer. Extensive 
studies on tumor pathogenesis have unveiled the impact of genetic alterations affecting 
proteins involved in the transcriptional control (Bradner J.E. et al, 2017). The tumorigenic 
process is characterized by alterations of the main transcriptional regulators that make normal 
cells more prone to proliferate, migrate and less sensitive to cell death. Thus, an approach to 
enrich cancer knowledges and find important therapeutic targets would be to discover the 
components involved in the deregulation of transcriptional programs in neoplastic cells on 
which the growth and survival of cancer cells depend on (Martin M.N. et al, 2018).  
In recent decades, the treatment of neoplasm has obtained promising results by targeting the 
oncogenic addictions (Weinstein IB. and Joe A., 2008). For example, EGFR is identified as a 
driver oncogene in non–small cell lung carcinoma, as well as c-kit in gastrointestinal stromal 
tumors and KRAS in pancreatic adenocarcinoma. Even if fascinating, the genomic instability, 
as well as the tumor heterogeneity, have reduced the promising results of hitting a single 
molecular target and a rational combination therapy is still required (Weinstein IB. and Joe 
A., 2008). 
In this project we investigated a new form of cancer addiction: the acquisition by cancer cells 
of an epigenetic mechanisms of addiction (Robison AJ. and Nestler E., 2011). In particular, 
our research focused on LMS for three main reasons: 1) LMSs are tumors with a not a 
completely defined panel of driver oncogenes (Tawbi HA. et al, 2017); 2) no advanced 
therapies have been developed yet; 3) we have shown, also thanks to the work of this thesis, 
that class IIa HDACs are highly active in high grade LMSs (Di Giorgio E. et al, 2013; Di 
Giorgio E. et al, 2017). Our previous studies led to the discovery that during the 
leiomyosarcomagenesis MEF2 family members are highly repressed and this is associated 
with increased tumor aggressiveness. In low grade LMS cells, this repression could be mainly 
due to decreased MEF2 protein half-life (Di Giorgio E. et al, 2013; Di Giorgio E. et al, 2017), 
while in high grade LMSs, MEF2 expression is stable and they are converted into 
transcriptional repressors through the engagement of class IIa HDACs.  
Among the four HDACs, a relevant role is played by HDAC9, that is over-expressed in one 
quarter of LMSs. The KO of HDAC9 in high grade LMS cells (SK-UT-1 cell line) removes 
its repressive effect on MEF2 and significantly reduces the transformed phenotype of SK-UT-
1 cells. These features are reflected by an accumulation of cell death and by a cell cycle arrest 
in G1 phase (manuscript in preparation), as previously reported for the knock-down of 
MEF2D and MEF2A in SK-UT-1 cells (Di Giorgio E. et al, 2017). Whether the arrest in G1 
could be due to a mitotic crisis is still under investigation.  
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The key role of HDAC9 in the malignancy of LMS suggests the crucial role of this protein in 
the tumorigenic process of uterine LMSs. 
However, the co-expression of MEF2 and HDAC9 is not limited to LMSs; evidences of their 
frequent correlation have been found also in other cancer types, such as in breast cancer and 
in pediatric leukaemias, reviewed by Di Giorgio E. et al. (2018). HDAC9 is also over-
expressed in basal breast cancer cells; here it is described to be required to sustain 
malignancy, survival and resistance to HDIs (Lapierre M. et al, 2016). 
High levels of HDAC9 have been reported also in B-ALL (B progenitor acute lymphoblastic 
leukaemias) cases, as a consequence of chromosomal rearrangements that give rise to 
chimeric fusion proteins (Gil VS. et al, 2016). In the last years, new frequent rearrangements 
between MEF2D and other genes (BCL9, CSF1R, DAZAP1, HNRNPUL1 and SS18) have 
been detected; specifically, the MEF2D-BCL9 fusion is responsible of an increased 
transcription of HDAC9 and at the same time, of a negative regulation of other MEF2 targets, 
such as RAG-1 (Gu Z. et al, 2016).  
In physiological contexts, the relationship between HDAC9 and MEF2D is strongly regulated 
by a negative feed-back loop, as demonstrated during the skeletal muscle development. MEF2 
is active in the transcription of genes fundamental for muscle differentiation, such as 
myogenin (MYOG), but also in the activation of HDAC9, which in turn regulates MEF2 by 
suppressing its transcriptional activity (Haberland M. et al, 2007). This sophisticated system 
serves to keep their expression levels balanced, thus supervising muscle differentiation 
programs. 
The co-existence of high levels of HDAC9 and MEF2D in cancer may be explained by an 
alteration of this circuitry (Di Giorgio E. et al, 2018). Curiously, we observed that in high 
grade LMSs, MEF2 are converted into transcriptional repressors through the binding of 
HDAC9 on certain genomic loci, but they maintain the role of transcriptional activators on 
other genes and also on the HDAC9 promoter. It this way, we speculate that in tumoral cells, 
MEF2 is entangled in promoting HDAC9 transcription in an altered mechanism enriched by 
the refractoriness of HDAC9 in binding and repressing its own transcription. We do not 
exclude that the altered feed-back established between HDAC9 and MEF2 in 
leiomyosarcomas could be responsible of the malignancy and aggressiveness of other cancer 
types. 
The epigenetic addiction derived from the co-expression of MEF2 and class IIa HDACs, 
which occurs in 25% of LMS, could be exploited to selectively target the complex between 
MEF2 and class IIa HDACs. By scrutinizing a panel of molecules, we selected a 
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pharmacological approach with the BML-210 analogue, NKL-54 (Jayathilaka N. et al, 2012), 
which predisposes them to cell death. In details, we found that this agent sensitizes the cancer 
cells to apoptosis, recapitulating the effect of HDAC9 knocking-out. Moreover, it increases 
the cytotoxic effects of other compounds, in particular of Doxorubicin. 
The anti-proliferative effects of synthetic benzamides on cancer cells, such as the BML-210 
and its derivatives, were recently reported. Borutinskaitė V. and Navakauskienė R., in 2015, 
described how BML-210 is able in promoting a significant growth inhibition, by provoking 
increased levels of p21 expression, and apoptotic cell death of a promyelocytic leukemia cell 
line (NB4).  
Several clinical and preclinical studies suggest the potential of the HDAC inhibitors for the 
treatment of different types of cancers, alone or in combination with standard doses of other 
cytostatic drugs (Marek L. et al, 2013). The majority of the data report the synergistic effects 
of the HDACi when combined with DNA-damaging chemotherapeutic agents or radiotherapy 
(Wagner JM. et al, 2010; Thurn KT. et al, 2011). For example, combination therapies of the 
deacetylase inhibitor Vorinostat with the DNA-methyltransferase inhibitor Decitabine, or with 
the proteasome inhibitor Bortezomib, have proved encouraging results in different 
haematological malignancies (Wagner JM. et al, 2010). Also patients affected by advanced 
prostate cancer show positive effects when treated with a combination of Panobinostat and the 
antimitotic chemotherapeutic agent Docetaxel (Rathkopf D. et al, 2010). 
Combination therapies with more selective member-specific inhibitors are currently 
investigated, including also class IIa HDACs specific inhibitors. The discovery of these 
inhibitors may allow the development of new therapeutic drugs that could circumvent the side 
effects obtained with traditional hydroxamate-based compounds. Novel molecules are still 
under identification through increasingly sophisticated screening methods, as recently 
published by Hsu KC. et al. (2017). Little is still known from literature about the therapeutic 
effects of these innovative compounds. Recently, a new potent HDAC inhibitor, LMK235, 
which is characterized by a selective preference for HDAC4 and HDAC5, has been developed 
(Marek L. et al, 2013). Interestingly, the combination of this compound with cisplatin 
significantly enhances the cisplatin sensitivity of ovarian and breast cancer cisplatin-resistant 
cell lines (Marek L. et al, 2013; Stronach EA. et al, 2011). The effects of BML-210 are 
similarly studied for its properties to sensitize malignant cells to other drugs, for example 
when associated with retinoic acid on HeLa cervical carcinoma cells (Borutinskaitė V. et al, 
2006).  
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Regarding advanced or metastatic uterine leiomyosarcomas, the standard first-line 
chemotherapy is represented by Doxorubicin, eventually combined with the alkylating agent 
Ifosfamide (Akin S. et al, 2018), with Gemcitabine, an inhibitor of DNA synthesis and repair 
(Momtahen S. et al, 2016), or with Olaratumab, a human monoclonal antibody against the 
platelet derived growth factor receptor alpha (PDGFR-α) (Okuno SH. et al, 2017). Moreover, 
Trabectedin (Recine F. et al, 2017) and the anti-PD-1 antibody Pembrolizumab (Tawbi HA. et 
al, 2017) have been recently approved in advanced soft-tissue sarcomas. 
Unfortunately, all these approaches, even if more innovative and specific for various 
molecular targets, are characterized by a limited effectiveness due to the high molecular 
heterogeneity of the tumor. 
Our study introduces an innovative approach for the treatment of high grade 
leiomyosarcomas, through a transcriptional re-setting. Our approach describes an alternative 
strategy to personalize the therapies, on the base of the expression levels of the two main 
actors of this tumor: HDAC9 and MEF2A/D. This transcriptional re-setting can potentiate the 
standard treatment approaches. In details, we propone the adoption of new epigenetic drugs, 
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